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Over the past few years there has been considerable
interest in the use of anti-idiotypic (anti-Id)
antibodies for immunotherapy of B-lymphocyte tumours. In
spite of some promising results clinical trials have been
restricted by the need to produce unique antibodies for
each patient to be treated. This study has attempted to
define recurring idiotopes in a group of k2 cases of
chronic lymphocytic leukaemia (CLL) with the ultimate aim
of using pre-existing anti-Ids to treat the disease. The
reactivity of a panel of Ik monclonal anti-Ids with
normal serum immunoglobulin (Ig) was determined using an
enzyme-linked immunosorbent assay (ELISA) technique. The
anti-Ids were divided into three groups; seven antibodies
reacting with determinants unique to the immunising
paraprotein, four antibodies reacting with public
idiotopes strongly expressed by serum Ig, and three
antibodies reacting with restricted public idiotopes, ie
with low levels of expression by serum Ig. Expression of
the various idiotopes by the CLLs was tested by indirect
immunoperoxidase. To confirm the specificity of cellular
reactions, cells from 18 patients were stimulated by the
phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA)
to secrete Ig in vitro. The presence of polyclonal Ig in
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the culture supernatants was found to be related to the
presence of autologous T-cells. Secreted tumour Ig was
tested for anti-Id specificity by ELISA. The majority of
cellular reactions were confirmed as Ig specific, but a
number of cross-reactions also occurred both in
unstimulated cells and after TPA stimulation. The results
confirmed that private idiotypic determinants are not
generally expressed by CLLs. However, the public
idiotopes are expressed by between 7% and 29% of cases
and the restricted public idiotopes also show variable
expression ranging from 5% to 1/1% of cases. The potential
value of the last group of antibodies as therapeutic




For many years one goal of tumour immunologists has been
to produce antibodies directed against tumour specific
cell surface components for therapeutic use (Currie,
1972). Early attempts at such immunotherapy were
frustrated by the heterogeneity of anti-sera and the side
effects associated with the administration of large
quantities of foreign proteins. Since the advent of
monoclonal antibody technology (Kohler and Milstein,
1975.) with the ability to produce unlimited amounts of
antibody against a single antigenic determinant, these
problems have been largely solved, but have been replaced
by those of defining suitable tumour cell antigens. The
ideal target for immunotherapy would be a stable epitope
expressed by the entire neoplastic clone but not by
non-malignant cells.
Unfortunately, the majority of tumour associated antigens
described are not absolutely specific for the malignant
cells as they are also expressed by normal cells at
certain stages of differentiation. The closest
approximation to a true tumour specific antigen is the
immunoglobulin (Ig) idiotype (Id) of those leukaemias and
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lymphomas of the B-lymphocyte series which express
surface immunoglobulin (slg). In the future it is
possible that T-cell receptor idiotypes expressed by
T-lymphocyte malignancies may also be exploited as tumour
specific antigens.
1.1. The Immunoglobulin Idiot.vpe
It is estimated that the immune system is capable of
generating up to 10s different antibody specificities
(Roitt et al, 1981.) partly by the control and
expression of the germline Ig variable (V) region heavy
and light chain genes, and partly by a process of somatic
mutation (Tonegawa, 1983). As a result each antibody
clone expresses unique V region associated antigenic
determinants collectively known as the idiotype; a term
derived from the Greek for "individual" and "form" and
first used by Oudin (1966).
Even before the structure of Ig was elucidated Slater et
al (1955.) showed that rabbit anti-sera against human
myeloma proteins would react with the original
paraprotein even after extensive adsorption with normal
Ig and other myeloma proteins; the first description of
an anti-idiotypic (anti-Id,) anti-serum. Similar
properties for normal Ig were described by Kunkel et al
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(1963,) who showed that human antibodies produced in
response to immunisation with dextran, levan and blood
group antigens expressed unique antigenic determinants.
These were localised to the Fab segment by Grey et al
(1965, ) and eventually to the Fv portion of the
immunoglobulin molecule (Wells et al, 1973).
Most idiotypic determinants require the interaction of
heavy and light chains for their expression (Carson &
Weigert, 1973.) and are therefore the products of 2
unrelated genes. There are, however, idiotypic
determinants which are localised on heavy (Yarmush et al,
1977; Zeldis et al, 1979, ) or light (Chen et al, 1984, )
chains and may be phenotypic markers of single variable
(V) region genes.
Williams et al (1968, ) had shown that IgM cold
agglutinins with similar antigenic specificity also
shared idiotypic specificity which was partly blocked
when the antibodies were bound to their antigens. Similar
findings for human IgM rheumatoid factors (Kunkel et al,
1973.) led to the generally held belief that the
antigenic and idiotypic specificities of an Ig molecule
were both dependent on the hypervariable regions of the V
genes and that the antibody combining site contained
the major idiotypic determinants (Capra, 1977).
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However, V region structures which are physically distant
from the antigen binding site can also be defined
serologically (Mudgett et al, 1978). These are generally
framework determinants common to V region gene families
or cross-isotypic epitopes (Rivat-Peran et al, 1980). In
addition it is possible that V region allotypes such as
have been described for the V» genes of rabbits (Kindt,
1975.) may also exist in humans. Such determinants are
not clone specific and are therefore not strictly
idiotypic but the term is frequently used to describe any
V region associated antigenic determinant.
Thus a picture has gradually emerged of the idiotype as a
complex structure expressing a number of different
antigenic determinants or idiotopes which are
structurally and functionally distinct (Rajewsky and
Takemori, 1983). Each idiotope can be defined by a
monoclonal anti-idiotypic antibody and the sum total of
all the individual idiotopes defines the idiotype.
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1.2. Anti-Idiotypic Immunotherapy of Human B-Cell Tumours
Any B-cell tumour which expresses slg can be considered a
candidate for anti-Id immunotherapy providing tumour Id
secretion is not excessive as high serum Id levels would
neutralise the therapeutic antibody. Thus the most
suitable tumours for this form of therapy are likely to
be chronic lymphocytic leukaemia (CLL), pro-lymphocytic
leukaemia (PLL), and the majority of the low and
intermediate grade non-Hodgkin's lymphomas (Ersboll et
al, 1985).
Practical experience has confirmed that it is relatively
easy to generate polyclonal (Stevenson & Stevenson.
1975.) and monoclonal (Thielemans, 1984-,) anti-Ids
against tumour associated Ig. Such antibodies are highly
specific for the malignant clone to the extent that a
unique antibody has to be produced for each patient to be
treated.
There are reports of 25 patients with B-cell tumours
being treated with anti-Ids since 1980 (table 1.1).
Although the overall results of treatment have been
disappointing there is clear evidence that such therapy
can have a significant anti-tumour effect. It must be
remembered when assessing these results that the majority
of the patients involved have had end-stage disease.
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often refractory to conventional forms of therapy.
Two groups have pioneered the use of anti-Ids as
therapeutic agents in human B-cell tumours. Stevenson's
group at the Tenovus Research Laboratory in Southampton
have reported treating a total of 7 patients with sheep
polyclonal anti-Id preparations and 1 patient with a
derivative of a monoclonal antibody (table 1.1).
Three patients with NHL did not show clinically
significant effects after polyclonal anti-Id therapy
(Macbeth et al, 1983,) but in 3 of H patients with CLL or
PLL treatment with polyclonal anti-Id was associated with
a marked reduction in circulating tumour cells and
evidence of cell death (Hamblin et al, 1980; Gordon et
al, 198£la). However, there was no reduction in palpable
disease and the blood counts returned to pre-treatment
levels within 3 days. No sustained beneficial effects
were seen in any of the patients.
Levy's group at Stanford University reported the first
apparent cure due to anti-Id therapy using a monoclonal
antibody raised against a private idiotypic determinant
from tumour specific Ig (Miller et al, 1982). The patient
had a non-Hodgkin's lymphoma which had undergone
transformation from a follicular to a more aggressive,
diffuse histology and was refractory to conventional
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cytotoxic therapy. Ten days after starting intravenous
infusions of a monoclonal IgG2b anti-Id the tumour showed
evidence of regression and ultimately the patient
achieved a sustained, unmaintained complete remission
which has currently lasted over 4 years. Biopsy of the
regressing lesion demonstrated large numbers of
macrophages and activated T-lymphocytes by
immunophenotyping (Levy and Miller. 1983).
This group have since reported their experience of using
monoclonal anti-Ids to treat 13 patients (12 with NHL and
1 with PLL). In 6 cases there was significant tumour
regression lasting up to 6 months but only the original
patient achieved a durable, complete remission (Meeker et
al, 1985. and Miller et al, 1987).
Two patients with NHL (Rankin et al, 1985.) and two
patients with CLL (Bertoli et al, 1984; Capel et al,
1985,) have also been treated with monoclonal anti-Ids




Clinical Trials of Anti-Id Therapy in Humans
Disease No. Pts. Anti-Id Reference
PLL 1 Poly > Hamblin et al, 1980
CLL 3 Poly > Gordon et al, 1984a
NHL 3 Poly Macbeth et al, 1983
NHL 12 Mono > Miller et al, 1982
PLL 1 Mono > Meeker et al, 1985
> Miller et al, 1987
CLL 1 Mono Bertoli et al, 1984
NHL 2 Mono Rankin et al, 1985
CLL 1 Mono Capel et al, 1985
CLL 1 Mono* Hamblin et al, 1987
PLL = Prolymphocytic Leukaemia, CLL = Chronic Lymphocytic
Leukaemia, NHL = Non-Hodgkin's Lymphoma, Poly =
polyclonal, Mono = Monoclonal.
No. Pts. = Number of patients treated with anti-idiotype
^Univalent chimeric derivative of monoclonal antibody
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1.3. Mechanism of Action of Ant1-Idlot.vpic Therap.v
It has been suggested that the anti-tumour effects of
anti-Id could be mediated by two entirely separate
actions (Stevenson & Stevenson, 1983.); i) direct
cytotoxicity and ii) immune regulation.
1.3.1 Direct Cytotoxicity
Tumour cells coated with therapeutically administered
anti-Id could be lysed by host immune effector mechanisms
such as complement or antibody dependent cellular
cytotoxicity (ADCC). Macrophages (Shin et al, 1975,
Langlois et al, 1981.) natural killer cells (Ojo and
Wigzell, 1978.) and killer lymphocytes (Cerrotini et al,
197*1, ) have all been suggested as the cell responsible
for destruction of antibody coated tumour cells.
There is evidence from animal models of tumour
immunotherapy that complement and ADCC can both mediate
tumour cell destruction (Bernstein et al, 1980,) but that
ADCC is the more important mechanism in vivo (Kirch and
Hammerling, 1981; Levy and Miller, 1983).
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1.3.2 Immune Regulation
As a target for immunotherapy the idiotype is unique, not
only because of its specificity for the malignant clone,
but also because it is a physiological receptor through
which clonal regulation is normally mediated.
There is circumstantial evidence that malignant B-cells
are capable of responding to such regulatory signals
(Jaffe, 1983,) and it is possible that therapeutic
anti-Id would induce immunoregulatory circuits which
ultimately control the malignant clone.
There is some evidence from the treatment of human
patients to support the participation of both these
mechanisms in the anti-tumour effect.
The first patient treated with polyclonal anti-Id by
Stevenson's group (Hamblin et al, 1980,) had a marked
reduction in serum complement levels associated with
therapy. Cells from U leukaemic patients treated by this
group were lysed in vitro in the presence of polyclonal
anti-Id when rabbit serum was used as a source of
complement although ABO compatible human serum was less
effective (Gordon et al, 198&a).
- 10 -
Results with monoclonal anti-Ids, however, have been
more variable. A post-therapy lymph node biopsy from a
patient with NHL revealed large numbers of lysed tumour
cells suggesting a cytotoxic effect (Rankin et al, 1985, )
and a patient with CLL treated with a derivative of a
monoclonal anti-Id showed some evidence of complement
activation in vivo although tumour cells were resistant
to complement and ADCC in vitro (Hamblin et al, 1987).
However, the patient achieving a complete remission in
the Stanford series (Meeker et al, 1985.) was treated
with an anti-Id which was not cytotoxic to the tumour
cells in vitro and had no effect on mitogen induced
proliferation in vitro (Lowder et al, 1987). In this
study the only pre-therapy parameter which did correlate
with the clinical response to anti-Id was the number of
T-lymphocytes in the tumour biopsy.
It is possible that more aggressive tumours are less
likely to respond to anti-Id therapy and also tend to
contain fewer normal cells. However, another explanation
could be that the infiltrating T-cells are part of an
ineffectual host immune response against the tumour which
is augmented by anti-Id therapy.
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Animal models have been used in an attempt to determine
which factors and by what mechanisms tumour response to
anti-Id therapy is mediated.
1.4 Animal Models
Only two models, the L2C guinea pig leukaemia and the
murine myelomas will be described in detail as they
provide evidence in favour of each of the two mechanisms
by which anti-Id therapy is thought to work.
1.4.1. LiC Guinea Pig Leukaemia
This spontaneously arising IgMA expressing leukaemia is a
useful model because the cells express high levels of slg
but do not secrete Ig.
In vitro studies showed that only the IgM and IgGl
fractions of polyclonal sheep anti-Id antisera were
capable of lysing tumour cells in the presence of
complement and that the IgG2 fraction could mediate ADCC
using sheep or human leucocytes (Stevenson & Elliot,
1978). Further studies with guinea pig and murine
peritoneal macrophages as the effector cells showed that
these cells were incapable of phagocytosing anti-Id
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coated tumour cells, were not directly cytotoxic but that
they did inhibit tumour cell proliferation in vitro
(Lawson & Stevenson, 1983). The in vivo significance of
these findings is uncertain and it may be that tumour
cell destruction is dependent on a variety of effector
functions.
Guinea pigs challenged with 2 x 10s tumour cells in vivo
invariably die within 20 days. Survival times were
slightly improved (by a median of three days,) by a
single dose of polyclonal sheep anti-idiotypic IgG
administered six hours after the tumour inoculum
(Stevenson et al, 1977).
The group then looked at the effects of active
immunisation with purified tumour Id prior to challenge
with tumour cells (Stevenson & Gordon, 1983,) and found
that all immunised animals developed anti-Id antibodies
capable of lysing LiC tumour cells in vitro in the
presence of complement. The immunised animals showed
clearly improved survival times (all the control animals
died around day 12, whereas all the immunised animals
died between days 19 and 26). Estimating the doubling
time of the tumour in vivo the authors concluded that a
high proportion of the tumour cells were destroyed but
there were no long term survivors.
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1.U.2. Murine Myelomas
Multiple myeloma in man is not a likely candidate for
anti-Id therapy as the tumour cells express little or no
Ig to serve as a target and also the large amounts of
serum idiotype would neutralise infused anti-Id. The
series of murine myelomas are different from the human
disease. They are morphologically heterogeneous including
small round slg positive lymphocytes as well as
classical plasmacytic forms. When an animal is challenged
with tumour the more plasmacytic cells die off rapidly
and serum Id levels remain low for a number of days until
the slg positive precursor cells differentiate into Ig
secreting forms (Lynch et al, 1979). During this period
idiotype specific manipulation of the tumour is possible.
The MOPC 315 myeloma is a tumour of BALB/c mice and
purified MOPC 315Id is capable of inducing a syngeneic
anti-Id response (Sirisinha & Eisen, 1971). Lynch et al
(1972,) were the first to show that immunising BALB/c
mice with purified MOPC 315Id provided 90% long term
protection from lethal challenge with the tumour and that
the protection was idiotype specific. The protective
effect was not associated with complement mediated lysis
nor with the levels of anti-Id in the serum (Frikke et
al, 1977).
- Ill -
Passive immunisation with large amounts of syngeneic
immune serum was capable of suppressing tumour growth
(Bridges, 1978). This group also reported that tumour
immunity could be mediated by adoptive transfer of spleen
cells from immunised animals to irradiated animals but
only when the recipient animals received a small dose of
tumour Id in addition.
Evidence that the protective effect involved more than a
simple antibody response was obtained when it was shown
that post-immunisation thymectomy abolished the
anti-tumour activity even though the serum anti-Id
levels were not significantly changed (Daley et al,
1978) .
Further studies found a population of Id specific
suppressor T-cells capable of inhibiting Id secretion in
vivo (Rohrer, 1979,) and of inhibiting tumour cell
proliferation and Ig secretion in vitro without being
directly cytotoxic (Flood et al, 1980; Milburn et al,
1982). Lynch & Milburn (1983,) showed that reduced Ig
secretion induced by suppressor T-cells in vitro was due
to reduced light chain transcription and production while
heavy chain production was reduced but mRNA transcription
was unaltered.
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Monoclonal anti-Ids were also shown to be capable of
suppressing myeloma cell growth and Ig secretion in vitro
(Kodama et al, 1986,) and of protecting animals from
tumour cell challenge in vivo (Bridges et al, 198U).
1.U.3' BCLi Murine Leukaemia
This spontaneously occurring IgM* leukaemia has
morphological and phenotypic characteristics similar to
the pro-lymphocytic variant of CLL in man (Krolick et al,
1979). Administration of polyclonal anti-Id before and
after challenge with a lethal dose of tumour cells
resulted in complete suppression of the malignant clone.
In vitro studies also showed reduced tumour cell
proliferation in the presence of anti-Id.
However, Ciavarra et al (1986, ) showed that some strains
of mice were naturally resistant to tumour challenge and
that this was mediated by T-cells. They further showed
that a response against both the BCLi idiotype and a
histocompatability antigen expressed by the tumour was
required for successful spontaneous immunity to the
tumour.
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1. ll. k CH Murine Lymphomas
This series of lymphomas were induced in response to
intense immunisation with sheep red blood cells (SRBC)
and were found to be transplantable (Lanier et al, 1982).
Original work on the CHI lymphoma had shown that
polyclonal anti-Id could completely protect animals from
tumour challenge (Haughton et al, 1978). Increasing the
dose of anti-Id resulted in reduced animal survival and
the authors concluded that the effects were probably
mediated by immune regulation rather than direct
cytotoxicity. Further work showed that the protective
effect of anti-Id was only mediated by the intact Ig
molecule and that it did not depend on either an intact
thymus or on complement (Lanier et al, 1980).
Polyclonal anti-Ids raised against 7 of the 27 B-cell
tumours characterised in the CH series showed significant
cross-reactivity with 21 of the tumours (Pennell et al,
1985). Not all of the cross-reacting tumours reacted with
SRBC and the authors postulated that the expression of
the recurring idiotypes could be related to a common
immunoregulatory defect making certain B-cell clones more
likely to undergo malignant transformation.
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1.4.5 Murine Lymphoma 141
Sugai et al (1974,) described this tumour which arose
spontaneously in stock NZB/NZW F1 mice which also have a
high incidence of auto-immune disorders. Mice immunised
with purified tumour Id and control animals both develop
tumour nodules 15 days after tumour challenge. In 3 out
of 5 immunised mice, however, the tumours regressed after
35 plus days. In vitro tests showed evidence of weak
humeral immunity but no evidence of ADCC. Spleen cells on
the other hand were cytotoxic for the tumour cells
suggesting that a cellular immune response was
responsible for the regression.
1.4.6 Murine Lymphoma 38C13
This carcinogen induced, transplantable, IgM expressing
lymphoma was produced in a T-cell depleted C3H/eB mouse
(Bergman & Haimovich, 1977 and Bergman, Haimovich &
Melchers, 1977). Perek et al (1983,) showed that mice
could be protected from lethal tumour challenge not only
by monoclonal anti-Id but also by the F(ab)i portion of
the parent molecule suggesting that the protective effect
was not dependent on complement or ADCC.
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Using the same model, however, Kaminski et al (1986,)
showed that monoclonal anti-Id was capable of mediating
ADCC in vitro. Using class-switch variants of the same
anti-Id clone they further demonstrated that an IgG2a
variant was more effective than other IgG isotypes both
at protecting mice from tumour challenge in vivo and at
mediating ADCC of tumour cells in vitro.
The immunisation of animals with tumour idiotype or
anti-Id prior to challenge with a relatively small dose
of tumour cells is far removed from the treatment of an
established lymphoma or leukaemia in man. There are,
however, a number of useful observations arising from
such models.
Different experiments using the same animal models often
provide conflicting evidence about the likely mechanism
of action. This suggests that both direct cytotoxicity
and immune regulation can be induced depending on factors
such as the isotype, specificity and dose of anti-Id.
There is clear evidence that malignant B-cells are
capable of responding to immunoregulatory signals both in
vivo and in vitro with long lasting effects. Such
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regulation is idiotype specific since the anti-tumour
effect of immunising mice with one tumour idiotype does
not extend to similar tumours expressing different
idiotypes. In addition idiotype specific T-cells capable
of inhibiting tumour cell growth and differentiation in
vitro have been identified.
If normal immunoregulatory signals are to be exploited
for the therapy of human B-cell tumours it is necessary
to understand the role of idiotype in the regulation of
the normal immune system and this is discussed in the
following section.
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1.5 Idiotypic Regulation in the Normal Immune System
1.5.1 The Idiotypic Network Theory
Soon after their discovery it was clear that idiotypic
determinants were associated with Ig diversity and
antigenic specificity (Williams et al, 1968 and, Kunkel
et al, 1973). The concept that the idiotype might play a
central role in immune regulation was first put forward
by Jerne (1971). His theory assumed that the total Ig
repertoire was very large and that the variable region of
each Ig molecule consisted of a paratope or antigen
binding site and a set of idiotopes or antigenic
determinants which were immunogenic. He proposed that the
immune system consisted of a series of interacting clones
of lymphocytes which were capable of stimulating and
suppressing each other through idiotypic interactions and
suggested the predominant outcome in a steady state must
be suppressive.
He also postulated that T-cells would be involved in
idiotypic interactions thus converting a series of
unrelated lymphocyte clones into an integrated system
capable of self-regulation.
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Jerne suggested a model of network regulation in which
the clonal expansion of B-cells stimulated by antigen
resulted in an increase in the concentration of their
idiotypic determinants to immunogenic levels. As a
consequence anti-idiotypic clones would be stimulated
and expanded and could further stimulate or suppress the
original clones depending on other factors. The idiotopes
expressed by the anti-idiotypic clones would be capable
of stimulating a third set of antibodies. The ultimate
outcome of these various interactions would be to return
the immune system to a state of equilibrium once the
antigen was removed.
Experimental support for Jerne's hypothesis has mostly
come from studies of inbred animals. For instance, the
antibody response in BALB/c mice to the bacterial antigen
phosphorylcholine (PC) is dominated by B-cell clones
expressing the T15 Id. After repeated immunisations with
PC, anti-idiotypic antibodies against the T15 Id are
produced (Kluskens and Kohler, 1974). Kelsoe and Cerny
(1979, ) showed that the numbers of T15 positive cells
peaked on day 5 and day 12 after immunisation while the
number of anti-T15 positive clones peaked on days 10/11
and after 13 days. The successive peaks of Id positive
and anti-Id positive clones is consistent with Jerne's
original model.
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Similar results have been ob
including the immune respons
in BALB/c mice (Schrater et
1979,) and to Micrococcus
(Brown and Rodkey, 1979).
ined with other systems
to trinitrophenyl (TNP)
al, 1979, and Bona et al,
lysodeikticus in rabbits
The absence of strain specific immunodominant idiotypes
in outbred populations make it difficult to study similar
systems in man. However, individuals hyperimmunised with
antigens such as tetanus toxoid can be shown to develop
auto-anti-idiotypic antibodies (Qeha, 1982,) and
circulating anti-Id positive lymphocytes (Qeha, 1983).
Another investigative approach has been to influence the
immune response by idiotype specific manipulation. For
instance, antibodies (Abl) produced in response to
Micrococcus lysodeikticus in outbred rabbits only share
idiotypic specificity once in 60 animals. Abl was used to
immunise a second, allotype matched, rabbit to produce an
anti-Id (Ab2) response. A third rabbit was immunised with
Ab2 to produce an anti-anti-Id (Ab3) response. If Ab3 was
used to immunise another animal which was then challenged
with the original antigen the resulting antibody response
was dominated by antibodies sharing idiotypic
specificities with Abl (Urbain et al, 1977).
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The authors suggest that Abl clones are normally
suppressed by Id specific Ab2 clones. Pre-treatment with
Ab3 temporarily suppresses the Ab2 clones allowing the
preferential expansion of Abl clones in response to
antigen.
Similar idiotypic manipulations have been described in
BALB/c mice immunised with TNP. An idiotype expressed by
the TNP binding myeloma MOPC 1x60 is normally a minor
component of the anti-TNP response (Bona and Paul, 1979).
Immunisation with £l60Id induces an anti-Id response which
results in a reduction of it60Id positive cells in
response to TNP (Bernabe et al, 1981b). This suppression
of 460Id positive clones is transferred to the progeny of
female mice immunised with ^60Id (Bernabe et al, 1981a).
Conversely, immunisation with anti-it60Id antibody induces
an anti-anti-il60Id response which results in the
inhibition of naturally occurring 460Id specific
suppressor T-cells (Bona & Paul, 1979, ) ultimately
resulting in an increase in Zl60Id positive cells (Bernabe
et al, 1981b).
Idiotype specific T-cells have also been shown to be
generated during the course of an immune response. Thus
Owen et al (1977.) demonstrated Id specific T-suppressor
cells produced in response to anti-idiotypic antibodies
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in A/J mice while Id specific helper T-cells are
generated in the immune response of BIO.A mice to hen egg
white lysozyme (Adorini et al, 1979,) and probably
augment the T15 Id response to PC in BALB/c mice
(Bottomly et al, 1979).
These results show that idiotypic interactions occur in
the normal immune response and can be used to manipulate
that response. The demonstration of Id specific T-cells
which can stimulate or suppress B-cells in the absence of
antigen may shed some light on the nature of the
idiotypic interactions which are involved in network
regulation although no single model of the idiotypic
network enjoys universal acceptance.
It is conceivable that disturbances in the normal
idiotypic regulation of B-cells could result in
uncontrolled clonal proliferation even though the
critical defect lies outwith the malignant population. If
such tumours do exist they would be ideal candidates for
idiotype specific immunotherapy.
There is also the possibility that any B-cell tumour
expressing slg would be susceptible to network regulation




Within a few years of the discovery of idiotypy evidence
began to emerge that some idiotypic determinants were not
specific for a particular antibody clone but were shared
by many different clones (Kunkel et al, 1973).
Shared or cross-reacting idiotopes in the normal immune
system must either be derived from genetically unrelated
B-cell clones which have been selected by virtue of
affinity for the same antigen or by related clones using
the same or similar variable region genes.
In the former case the shared idiotopes are likely to be
closely related to the antigen combining site and to
depend on intact immunoglobulin for their expression. In
the latter case the idiotopes concerned may be the
phenotypic markers of the expression of specific variable
region genes and may therefore be located on isolated
heavy or light chains.
Shared idiotopes have been well described in the immune
responses of inbred mice to a number of simple haptens
(Claflin & Davie, 1975: Makela & Karjanainen, 1977; Ju et
al, 1978). In such cases the shared idiotope can usually
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be shown to be the product of a specific germ line
variable region gene, usually from the heavy chain. The
cross-reacting idiotope from the anti-QAT response of
BALB/c mice has been localised to a specific amino acid
sequence in the second hypervariable region of the heavy
chain although its expression seems to depend on
combination with a specific light chain (Clevinger et al,
1980).
Even in an outbred population such as man it is possible
to identify shared idiotopes as in antibodies against
Rhesus antigens (Forre et al, 1977,) and hepatitis B
surface antigen (Kennedy & Dreesman, 1983). The majority
of shared idiotopes that have been described in man are
associated with auto-immune disorders for instance in
anti-thyroglobulin antibodies in Grave's Disease
(Matsuyama et al, 1983.) anti-acetylcholine receptor
antibodies in myasthenia gravis (Lefvert, 1982.) and in
non-organ specific auto-antibodies such as anti-DNA
antibodies (Diamond & Soloman, 1983.) and Rheumatoid
factors (Kunkel et al, 197^).
Immunoglobulins expressing shared idiotopes associated
with cold agglutinins (Feizi et al, 1977.) and Rheumatoid
factors (Goni et al, 1985; Fong et al, 1986,) have been
shown to utilise a restricted number of V region genes.
In such instances the shared idiotopes are phenotypic
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markers of these genes.
Thus there is evidence in health and in disease that
shared idiotopes are the products of specific V region
heavy or light chain genes. The incidence of shared
idiotopes in auto-immune disorders is most interesting
and suggests that specific clones or V region genes are
particularly likely to be involved in disordered
immunoregulation.
The conservation of specific V region genes and their
idiotypic determinants by the normal immune system
would strongly suggest that there are selective
pressures favouring their retention and expression. One
possible explanation would be that such shared idiotopes
have specific roles in the normal regulatory processes of
the idiotypic network.
1.5.3 Regulatory Idiotopes
In the early 1980s Bona and his colleagues put forward a
theory that the immune system preferentially used a
specific set of idiotopes for internal regulation (Bona
et al, 1981, Paul & Bona, 1982, and reviewed by Bona,
1987). They attempted to prove this using mouse myelomas
as models.
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Idiotypic Ig from the ABPC48 and UPC10 myelomas of BALB/c
mice share antigenic specificity for the P2-6
polyfructosan linkages found in bacterial and grass
levans. In addition they share a number of cross-reacting
idiotopes some of which are not inhibited by antigen and
are therefore distant from the antigen combining site
(Bona et al, 19&H). Genetic analysis demonstrates that
both myeloma idiotypes use the same V« subgroup derived
from a single germline V» gene (pHUl-U) (Olio et al,
1981) .
BALB/c mice immunised with AU&Id (Abl) produced an
anti-Id (Ab2) response. Ab2 antibodies were then used to
generate Ab3 which were used to generate AbU antibodies
in other mice. If each antibody expresses a set of
idiotopes all of which are immunogenic then each anti-Id
response should result in the generation of a new and
unrelated set of antibodies.
However, when Bona looked at
these antibodies he found
shared All& idiotopes and were
and Abk.
the binding properties of
that Abl and Ab3 antibodies
both capable of binding Ab2
In order to explain these results he postulated that Abl
expressed a special set of "regulatory idiotopes" which
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were preferentially used by the immune system, so that
immunisation with Ab2 results in the activation of clones
bearing the A48 regulatory idiotopes.
An alternative explanation is that since the Ab2 response
is polyclonal it will consist of different clones of
B-cells linked only by a common affinity for antigenic
determinants on Abl. It is therefore possible that the
expression of immunogenic idiotopes by these
heterogeneous clones is not sufficient to stimulate a
true Ab3 response whereas the common specificity they
share for Abl gives rise to the preferential stimulation
of clones expressing similar idiotypic determinants to
Abl. If this were so then the use of a monoclonal Ab2
with a single, uniform set of idiotopes would induce a
true Ab3 response which would consist of antibody clones
idiotypically and genetically unrelated to Abl.
However, the immunisation of BALB/c mice with different
monoclonal anti-A48Ids (Ab2) still resulted in the
stimulation of clones bearing Atl& idiotopes including
both levan binding and non-binding molecules (Legrain and
Buttin, 1983).
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The A48 Id system can also be used to investigate normal
immune responses, since non-immunised BALB/c mice have
naturally high titres of anti-levan antibodies, only a
minor population of which express A48 idiotopes.
Immunisation with levan does not stimulate A48 Id
positive cells possibly due to naturally occurring A48 Id
specific T-suppressor cells (Liebermann et al, 1979).
However, Bona discovered that A48 Id positive clones
could be preferentially stimulated by administration to
neonatal animals of either a minute amount of anti-A48
Id or A48 Id (Bona et al, 1984). Giving A48 Id also
resulted in the production of idiotype specific T-helper
cells which, presumably, had a positive regulatory
effect.
Bona interpreted this as further evidence that A48
cross-reacting idiotopes have a special role in clonal
regulation and performed further experiments with the
related myeloma protein UPC10 which was used to immunise
pregnant mice. When their progeny were subsequently
challenged with bacterial levan the antibody response was
dominated by UPC10 positive clones and idiotype specific
T-helper cells were also detected (Bona et al, 1984).
As a result of these experiments Bona has suggested that
regulatory idiotopes can be defined by the following
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criteria:
i. They are autoimmunogens.
ii. They are recognised by regulatory T-cells and have
the potential to become dominantly expressed as a
result of such interactions.
iii. They are the products of conserved V region germ
line genes and therefore recurring within species.
iv. They are shared by antibodies with varying
antigenic specificities.
The concept of regulatory idiotopes has enormous
implications for anti-idiotypic therapy of B-cell
tumours. Activating T-cell clones with specificity for a
regulatory idiotope expressed by surface Ig may be the
key to controlling the malignant cells. Successful
anti-Id therapy would then depend on the identification
of the most appropriate idiotypic targets.
Using the ABPC&8 mouse myeloma model Bona's group have
obtained experimental evidence that the target idiotope
may be crucial to the outcome of idiotype based
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immunotherapy. BALB/c mice were immunised with 1 of 111
different monoclonal Ids all derived from the same germ
line Vh genes and all sharing idiotopes with A*l8Id. All
antibodies induced a similar anti-Id response but only 5
of them protected immunised mice from challenge with
ABPC/18 myeloma cells (Rubinstein & Bona, 1986).
The detection of specific regulatory idiotopes amongst
the set of idiotypic determinants expressed by each
tumour is, however, a far more complex problem in man
than it is in an inbred laboratory animal.
1.6 Anti-Id Production
The ideal immunogen is purified tumour specific idiotype,
a problem in tumours likely to respond to anti-Id therapy
since these, largely, do not secrete Ig. However, it is
possible to produce sufficient amounts of Id from such
tumours in vitro by forming heterohybrids between tumour
cells and mouse myelomas cells and selecting variants
which secrete human Ig (Brown et al, 1980).
Chooosing between polyclonal and monoclonal anti-Id as a




Polyclonal anti-Ids can be fairly easily raised by
immunising an animal such as a sheep with tumour Id and
adsorbing the antibodies produced with normal human Ig
to remove activity against Ig isotypes and allotypes.
This will, however, result in the loss of reactivity
against idiotopes commonly expressed by normal Ig and
these may include regulatory idiotopes.
The resulting anti-Id preparation will contain antibodies
from a variety of different B-cell clones reacting with a
variety of idiotypic determinants on the tumour Ig and
may therefore show high avidity in binding tumour Id.
Large amounts of purified Id would be required for
anti-Id production which would also have the disadvantage
of batch variation. Nevertheless, polyclonal anti-Id can
be quickly produced and high avidity would be
advantageous for cell lysis via ADCC or complement.
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1.6.2 Monoclonal Anti-Ids
Monoclonal antibodies have the advantages that they can
can be produced in unlimited quantities without batch
variation. They can also be generated using much smaller
amounts of the immunogen although the process is
complicated, time consuming and expensive.
Antibodies against private idiotypic determinants can be
produced fairly easily by selecting and cloning hybrids
which react with the tumour idiotype but not with other,
unrelated paraproteins or with pooled normal
immunoglobulin (Qiardina et al, 1985). The production of
antibodies against shared idiotopes would be much more
complicated as large numbers of hybrids showing
restricted reactivity with a small panel of paraproteins
may have to be cloned and further characterised (Walker
et al, 1987).
Since a monoclonal antibody reacts with a single epitope
avidity is unlikely to to be as high as in a polyclonal
preparation but the specificity of monoclonal anti-Ids
would make them most appropriate for therapy dependent on
effects on regulatory idiotopes.
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1•7 Selection of Monoclonal Anti-Ids for Tumour
Immunotherapy
Conventional strategy relies on producing anti-Ids
against private idiotypic determinants with the
expectation that such reagents offer the advantage of
absolute specificity for the malignant clone. However,
the production of a unique anti-Id for each patient to be
treated may be impractical on a large scale. In the
Stanford trial it took an average of 1 year between
selecting a patient as a candidate for therapy and having
a monoclonal anti-Id available for therapeutic use
(Thielemans et al, 1984).
Private determinants are also characteristic of somatic
mutations and may therefore be prone to further mutations
associated with changes in idiotype expression in time
(Rajewsky & Takemori, 1983).
Furthermore, if successful anti-Id therapy depended on
selecting antibodies against specific regulatory
idiotopes then the random selection of antibodies against
private determinants will not be optimal and this may
explain the variable results of clinical trials.
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1.8 Cross-Reacting Idiotopes in B-Cell Tumours
An alternative approach would be to identify idiotopes
which recurred at significant frequencies within a group
of tumours and to produce a panel of antibodies against
such determinants.
The Stanford group looked for evidence of shared
idiotopes amongst their patients but found no
cross-reactions in 100 different lymphomas with a panel
of 15 monoclonal anti-Ids (Thielemans et al, 1984).
However, as the authors themselves point out, the
screening methods used to select anti-Ids in their
studies favoured the selection of antibodies against
private determinants.
Using a different screening protocol Stevenson et al
(1986,) demonstrated that it is possible to generate
monoclonal anti-Ids against public determinants of tumour
idiotypes but also pointed out that the expression of
such idiotopes by normal serum Ig could prevent infused
anti-Id from reaching the tumour cells. Rankin and Hekman
(1984,) have also reported that 2 monoclonal anti-Ids
produced against individual NHL idiotypes cross-reacted
with 1 out of 45 other NHLs.
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Mayumi et al (1982,) found that an anti-Id against Ig
expressed by a case of acute lymphoblastic leukaemia
reacted with 1-3% of normal B-lymphocytes and plasma
cells. Kiyotaki et al (1987,) used 39 anti-Ids to screen
28 different paraproteins and found that 5 of the
antibodies reacted with one or more paraprotein. Walker
et al (1987,) produced a panel of 1H anti-Ids against a
single paraprotein and extensively characterised them
against a panel of 159 paraproteins and 50 normal sera.
Seven of the antibodies reacted, in varying degrees, with
paraproteins other than the immunogen.
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There are a number of possible explanations for the
recurrent expression of idiotopes by different tumour
populations thought to arise randomly from the total
B-cell pool.
i. They could simply be phenotypic markers of a
common V region gene and the high expression in
the tumour population a reflection of their
expression in the normal B-cell pool.
ii. They could be phenotypic markers of a particular V
gene rearrangement which is associated with the
process of malignant transformation.
iii. A common idiotope may be expressed by genetically
unrelated clones if they are all selected by a
common antigen. Thus a network defect involving
idiotype specific T-cell regulation could result
in the oligoclonal expansion of B-cell expressing
the relevant Id.
iv. Finally, the shared idiotope could be a regulatory
idiotope expressed by the malignant B-cells either
because it is commonly expressed by normal B-cells
or because a specific regulatory defect results in
clones expressing that idiotope being more
susceptible to malignant transformation.
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The last two posslbilites are particularly relevant to
anti-Id therapy since tumours associated with a defect in
immunoregulation might be particularly susceptible to
immunotherapy.
This work is concerned with the identification of shared
idiotopes in normal Ig and within tumour populations. The
aim will be to define a group of idiotopes which are
recurrently expressed by B-cell tumours but which are
detectable only at very low levels in normal Ig.
If such determinants can be defined they could be
valuable tools for further investigating the biology of






The /J.5 patients involved in this study had chronic
lymphocytic leukaemia (CLL) as defined by conventional
morphological and immunocytochemical criteria (Gale,
1985). All the patients attended the Haematology
Department at the Western General Hospital, Edinburgh and
were from a group of about 60 patients who have been
followed up for a number of years.
Diagnostic investigations included peripheral blood and
bone marrow morphology, phenotyping by indirect
immunofluorescence, indirect immunoperoxidase and
rosetting with mouse erythrocytes before and after
treatment of the lymphocytes with neuraminidase. All
patients were fully phenotyped before inclusion in this
study.
Patient characteristics are shown in tables 2.1, 2.2 and,
2.3. Sixteen patients had stage A disease 15 had stage B
and, l/l had stage C (Binet et al, 1981). During the study
1 patient changed from stage A to B and 3 changed from
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stage B to C. Twenty eight patients had never received
cytotoxic therapy and only 9 out of 17 patients who had
been treated were on therapy at the time they were
sampled. There were 17 IgMn, 18 IgMA, 5 IgGn, 2 IgGA and,
1 IgAk and 2 IgAA expressing tumours.
2.2 THE JS MONOCLONAL ANTIBODY PANEL
This panel of 14 monoclonal antibodies (McAbs),
generated against a single IgGA paraprotein from a
patient with lymphoplasmacytoid lymphoma, was a gift from
Dr. J.A. Habeshaw (ICRF Oncology Unit, St. Bartholomew's
Hospital, London). Each antibody was characterised by
determining its specificity for isolated heavy and light
chains of the immunogen and its reactivity with 50
normal sera and 159 paraproteins (table 2.k,)(Walker et
al, 1987).
The V region specificity of the 14 McAbs is suggested by
their reactivity with the Fab fragment of the immunogen
and by the patterns of inhibition of binding to the
immunogen by other monoclonals to variable and constant
region epitopes. The idiotypic specificity is suggested
by the normal distribution of reactivity with the normal
sera; a pattern which would not be seen with allotypic
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determinants (Walker et al, 1987). It remains possible,
however, that antibodies which reacted strongly with the
normal sera and frequently with the paraprotein panel
(IXU.3C6, U.IX.3C1, Hk.lxBIX and, 47-5A2,) may detect variant
constant region epitopes expressed by Fab or variable
region framework determinants which may not be strictly
idiotypic.
Seven of the JS McAbs (2G5. DPF11, 1B2, IX9.&BH, 47.1B2,
47.1D5, and 47.2B3.) react with private determinants
which are almost unique to the JS paraprotein. These
antibodies showed weak binding to normal serum and, apart
from 2G5. DPF11, and 1B2 which all reacted with the same
IgM paraprotein, did not react with any of 159
paraproteins (Walker et al, 1987).
The remaining 7 antibodies react with V region associated
epitopes which are expressed to varying degrees by normal
serum and the paraprotein panel (Walker et al, 1987-)
Antibodies Uk.3C6, H-U.3C1, HU.UBll, and 47.7B3 react with
lambda specific determinants while UU.2A1, 2H3.D6, and
45.7A2 react with heavy chain specific epitopes expressed
by paraproteins with differing isotypes. A further
antibody (49.3C1,) was found to detect the IgG allotype
Glm(f) (Walker et al, 1987,) and was included in the
panel.
- 43 -
All the antibodies are IgGl subclass and were supplied as
ascites preparations which were aliquoted and stored at
-70* C.
2.3 METHODS
2.3-1 Cell Collection and Preparation
Venous blood samples (15mls) were taken from patients and
mixed with 2mls of 2% (weight/volume) disodium
ethylenediamine tetra-acetic acid (EDTA) in a universal
container. Peripheral blood mononuclear cells (PBMNC)
were then separated by layering the whole blood onto
lymphopaque (Nycomed Diagnostics,) (density - l,086g/ml.)
and centrifuging for 20 minutes at 500g. The layer of
cells at the interface of plasma and lymphopaque was
removed and washed three times in RPMI-16/J.0 (Gibco).
2.3.2 Cell Counting
The cell suspension was counted in an improved Neubauer




Three mis of sheep blood was washed 3 times in phosphate
buffered saline, pH 7-3 (PBS) and 1ml of packed red blood
cells was mixed with 1ml of 0.1 unit/ml of neuraminidase
(Sigma N 2876,) and incubated at 37' C for 30 minutes. The
treated cells were washed a further 3 times in RPMI,
resuspended in RPMI and counted. The treated sheep cells
were added, at a ratio of 40:1, to PBMNC in lOmls
RPMI-1640 with 10% fetal calf serum (FCS) and incubated
at 37*C for 10 minutes. The cells were then centrifuged
for 3 minutes at 60g and incubated for a further 45
minutes at 0*0. The cells were gently resuspended using
a pipette and layered onto lymphopaque and centrifuged
for 20 minutes at 500g. The cells at the interface of
RPMI and lymphopaque were then collected using a pipette
and washed three times in RPMI. Such cells were referred
to as "E-depleted cells."
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2.3.4- Preparation of Cell L.vsate
100 x 10' cells were washed 3 times in RPMI and
resuspended in 2 mis of PBS. Two mis of 1% Nonidet P-40
(NP-40,) in PBS containing 2 mM phenylmethyl sulphonyl
fluoride (Sigma) was added, thoroughly mixed and
incubated at 0*C for 30 minutes. After this time the
samples were centrifuged at 2000g for 15 minutes and the
supernatants kept at 4* C.
2.3.5 Cell Culture
The culture medium consisted of RPMI-1640 with 25mM
4-(2-hydroxyethyl)-l-piperazineethane sulphonic acid
(HEPES) (Gibco 041-2402) containing 2mM L-Glutamine
(Gibco 043-5030), ImM sodium pyruvate (Gibco 043-1360),
50 units/ml Penicillin and Streptomycin (Gibco 043-5140)
and 10% FCS (Northumbria Biologicals). Two batches of
FCS were used during this study which were selected for
their ability to support normal and CLL PBMNC
proliferative responses to stimulation with the mitogens
phytohaemagglutinin (Difco Labs, ) and the phorbol ester
12-0-tetradecanoylphorbol 13-acetate (TPA) (Scientific
Marketing Associates).
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Cells were cultured at 37* C in humidified air with 5%
COj. 10 x 10' cells were added to 70ml tissue culture
flasks (Costar 3055,) containing lOmls of medium.
Immunoglobulin secretion was induced by lOOng/ml of TPA
and the culture supernatants were collected after 6 days
(Polliack et al, 1986). Supernatants were stored at U' C
with a final concentration of 0.1% (weight/volume)
sodium azide in deionised distilled water (DDW).
2.3.6 Cr.vopreservation of Cells
Cells were suspended in FCS at 10 x 10'/ml and kept at
k' C for 10 minutes. Dimethyl sulphoxide was added to a
final concentration of 10% (volume/volume) and the cells
quickly transferred to 2 ml cryopreservation vials
(Costar 2028). The vials were placed in a polystyrene
box, put into a -70* C deep freeze overnight and
transferred to liquid nitrogen the following day.
Cells were recovered by taking a vial from liquid
nitrogen, warming it in a 37*C waterbath and transferring
the cells into lOmls of pre-warmed culture medium
containing 10% FCS before they had completely thawed. The
cells were then centrifuged at 150g for 8 minutes, the
supernatant poured off and replaced with another 10 mis
of pre-warmed culture medium. The cells were then counted
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and viability assessed as previously.
2.3.7 Purification of IeM
Serum containing a monoclonal
22g/l was obtained from a
Macroglobulinaemia.
IgMK paraprotein band of
patient with Waldenstrom's
2.3.7.1 Boric Acid Precipitation
10ml of serum was added to 190ml of 2% (weight/volume)
boric acid (B(OH)j ) in DDW for 30 minutes, then
centrifuged for 30 minutes at 1200g and the supernatant
discarded. The precipitate was washed twice in 2% boric
acid and redissolved in 10ml tris buffered saline (TBS)
(0.1M tris, 0.5M NaCl, pH 8.1 with 1M HC1.) according to
Mauch et al (1980).
2.3.7.2 Gel Filtration
A 100cm column (Pharmacia C 26/100,) was packed with
Sepharose 6B, attached to a peristaltic pump (LKB
Varioperex,) and washed with TBS. The sample was
centrifuged at 1200g for 10 minutes and any precipitate
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discarded. The supernatant was layered onto the column
and run at 3mls per minute. 6ml fractions were collected
by an automated fraction collector (Gibson Microcol TDC
80). The protein content of samples was estimated by
measuring UV absorbance at 280nm using a
spectrophotometer (Pye Unicam SP6-550 UV/VIS,) and
samples from a single peak were pooled.
2.3.7.3 Protein Concentration
Protein in the eluate from the column was concentrated by
positive pressure ultrafiltration using a filter with a
lOkD cut-off (Diaflo ultrafilter PM10,) and a pressure of
55 psi. The sample was concentrated to approximately
lmg/ml as judged by absorbance at 280nm (Johnstone and
Thorpe, 1985) •
2. 3-7.il Protein assay
This assay was adapted from the method of Bradford
(1976). 20ul of each sample was placed in duplicate wells
of a micro-ELISA plate (Dynatech M2H U well,) and 20^1 of
PBS added to separate wells as negative controls.
Standards consisted of doubling dilutions of bovine
albumin (Sigma A-H503, ) from lmg/ml. Protein assay
- U9 -
solution (Bio-Rad 500-0006, Gaston Way, Watford,) was
diluted 1:5 in DDW and filtered. 200p,l of this solution
was added to each well and left for 15 minutes. Optical
density at 620nm was measured in a plate reader (Titertek
Multiscan MC 340.) which was zeroed with 200p.l of the
diluted Bio-rad solution. The protein concentration of
the unknown samples were then estimated from the standard
curve (figure 2.1).
2.3.7.5 Polyacrylamide Gel Electrophoresis (PAGE)
PAGE was run using the Pharmacia Phastsystem according to
the manufacturers recommendations. The samples were run
on a pre-formed 0.45mm 10-15% gradient gel under reducing
conditions. The gel buffer was 0.112M acetate and 0.112M
tris, pH 6.4 and the elctrode buffers were 0.20M tricine,
0.2M tris and 0.55% sodium dodecylsulphate (SDS) pH 7.5
in 2% Agarose strips. lOOptl of the samples were added to
30y.l of a mixture of 40mM tris, 4mM EDTA, 10% SDS and,
20% dithiothreitol, pH 8.0 with 1M HC1, and boiled for 2
minutes immediately prior to running the gel.
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2.3.7.6 Radial Immunodiffusion
1% Agarose (weight/volume) was dissolved in PBS and
cooled to 60* C. 1ml of anti-Ig anti-sera (Scottish
Antibody Production Unit,) (SAPU,) was added to 25mls of
agarose, poured into a plastic petri dish (diameter 9cm,)
and left to set on a levelling table. 2mm circular holes
were made using a gel punch and the agar plugs removed.
10^.1 of each test sample, undiluted and 1/10 in PBS, was
added to the appropriate wells, the lids replaced and the
petri dishes left at it* C overnight. The plates were
examined for precipitation lines the following morning.
2.3.8 Immunocvtochemistrv
2.3.8.1 Cytospin Preparation
lOOu.1 of a cell suspension at 1 x 10' /ml in RPMI was
added to the carrier of a Shandon Cytospin II. The
addition of 5% FCS was beneficial in cases with
consistently poor morphology. The cells were centrifuged
at 500rpm for H minutes, and the slides were allowed to
dry in air for 2 minutes before being fixed in fresh
acetone for H minutes. The slides were again dried in
air, wrapped in polythene bags and either stored at lx* C
or at -20*C if they were not to be used within two weeks.
2.3.8.2 May-Grunwald Giemsa's Stain
Slides were fixed in absolute methanol for 10 minutes and
transferred directly to May-Grunwald's stain for 10
minutes and then to Giemsa's stain diluted 1:20 in
Sorensen' Buffer, pH 6.8, for a further 10 minutes. The
slides were then washed three times in Sorensen's buffer
and left to stand for 2 minutes for differentiation to
take place. The slides were then air dried and mounted in
Histomount.
2.3-8.3 Indirect Immunoperoxidase
The method was adapted from Salter et al, (1985- )
Acetone fixed slides were rehydrated with with 50p.l of
TBS (0.5M tris, 1M HC1, pH 7.6,) containing 20% normal
rabbit serum (NRS.) After 10 minutes excess fluid was
tipped off and 50^.1 of the primary antibody diluted in
TBS/NRS was added and incubated in a wet box for 30
minutes. The slides were then washed in TBS for five
minutes twice, the area around the cells was wiped with a
tissue and 50ul of rabbit anti-mouse Ig conjugated to
peroxidase (Dako P-260,) diluted 1:20 in TBS/NRS added.
After 30 minutes the slides were washed twice in TBS for
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five minutes. The areas around the cells was wiped dry
and the slide flooded with freshly prepared substrate
(lmg/ml diaminobenzidine in 0.02M tris-HCl with 0.01M
imidazole, pH 7.6). lOOp.1 of 1% Hi Oi was added to the
substrate immediately before use and the reaction was
stopped after 5 minutes by immersing the slides in water
for 2 minutes. The slides were then counterstained in
haematoxylin, washed in water and then briefly dipped in
lithium carbonate. After washing in water again the
slides were dehydrated through alcohol to xylene and
mounted in Histomount.
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2.3.9 Enzyme Linked Immunosorbent Assays (ELISA)
2.3.9.1 Materials
96 well Micro-ELISA plates (Dynatech M24 U well)
Capture antibodies:-
Polyclonal goat anti-human Ig (Sigma 1-9631)
Polyclonal goat anti-mouse Ig adsorbed
against human serum proteins (Sigma M-8645)









Washing and Blocking Buffer
0.05 M NaiHPO* containing 0.5M NaCl,
2.5g/l gelatin, 1% Tween-20, adjusted to
pH 7.7
Substrate Buffer
0.1M glycine containing 0.01M MgClj and
0.01M ZnCl1 adjusted to pH 10.4 with 5M
NaOH
Plate reader:- Titertek Multiscan MC 340 (Flow Labs)
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2.3.9.2 Three-Stage Immunoglobulin Assay
The Ig content of culture supernatants was quantitated
using an ELISA assay modified from the method of Lems-Van
Kan (1983. ) The micro-ELISA plates were coated with IOOm.1
of polyclonal goat anti-human Ig antibody at 100us/ml
in PBS and incubated at room temperature for 60 minutes.
The plates were washed k times in washing buffer and left
for k minutes during the final wash to block unbound
sites. IOOm-1 of each culture supernatant was added to
duplicate wells and incubated for a further 90 minutes.
After a further k washes in blocking buffer lOOul of goat
anti-human Ig alkaline phosphatase conjugate diluted in
blocking buffer was added and incubated for 90 minutes.
The optimal dilution of each conjugate varied between
batches but a protein concentration of 2pig/ml was
generally satisfactory. After k washes in blocking buffer
200p.l of p-nitrophenyl phosphate disodium (Sigma 10H,)
freshly diluted in substrate buffer was added. The plates
were read at £t05 nm after il0-/15 minutes at room
temperature.
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2.3-9.3 Quantitation of Ig
Ig levels in culture supernatants were quantitated by
comparison with dilutions of calibrated normal serum
(Protein Reference Unit, Royal Hallamshire Hospital,
Sheffield). A single batch of serum, containing 9.97mg/ml
IgG, l.lOmg/ml IgM and, 1.69mg/ml IgA, was used
throughout the study. Standard curves for each of the Ig
assays are shown in figures 2.2, 2.3 and, 2. 4.
It was possible that competition by the different
isotypes in the calibrated serum for the anti-human Ig
capture antibody might affect the results. This would
particularly apply to the IgM and IgA assays where the
high levels of IgG could block the available binding
sites. In order to assess the effects of such competition
IgM was purified from the serum of a patient with
Waldenstrom's Macroglobulinaemia as described previously.
Two protein peaks were separated by gel filtration
(figure 2.5,) and radial immunodiffusion using anti-heavy
chain specific anti-sera (SAPU) demonstrated IgM only in
samples from the first peak and mixture of IgG and IgA
in the second peak (table 2.5). Samples 36-40 from the
first peak and 52-54 from the second peak (figure 2.5,)
were pooled and concentrated. The absence of
contaminating proteins was confirmed by SDS-PAGE (plate
2.1,) and the protein concentration in the IgM
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containing sample determined using the protein assay
described previously. Standard curves for IgM using the
calibrated normal serum and purified IgM at the same
concentrations of IgM show reduced binding with the
serum, probably as a result of inhibition by IgG and IgA
(figure 2.6). Thus accurate quantitation of Ig using
polyvalent anti-Ig capture antibody with diluted normal
serum for the standard curves is not possible. Since
absolute quantitation of Ig was not essential for this
work the calibrated serum was used for all assays.
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2.3-9.4 Four-stage Idiotope Specific Assay
Micro-ELISA plates were coated with lOOp.1 of goat
anti-mouse IgG antibody at 2ug/ml in PBS and incubated at
room temperature for 60 minutes. They were then washed 4
times in washing buffer and left to stand for 4 minutes
during the final wash to block unbound sites. All the JS
McAbs were used at 1:90 in the blocking buffer and
anti-K and anti-X (SAPU) were used at 1:40 and 1:90
respectively. The plates were Incubated for a further 90
minutes at room temperature, washed 4 times in blocking
buffer and lOOp.1 of human Ig preparation (culture
supernatant or serum,) was then added and incubated at
room temperature for 90 minutes. After a further 4 washes
in blocking buffer lOOp.1 of the appropriate goat
anti-human Ig alkaline phosphatase conjugate diluted in
blocking buffer was added and incubated for 90 minutes.
The plates were developed and read as before.
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TABLE 2.1
Characteristics of Clinical Stage A Patients








JB M 72 1985 IgMX 10/85 10. 8 42 N
HB F 71 1986 IgM A 1/86 17. 3 52 N
PC M 73 1985 IgMK 6/86 15. 6 56 N
AD F 72 1982 IgGA 6/87 16. 2 68 N
WG M 69 1978 IgMK 3/86 11. 6 71 N
EG F 65 1983 IgMX 8/87 16. 8 76 N
MG F 60 1975 IgMK 6/87 6.2 35 Y
AG F 72 1984 IgMK 11/85 13. 1 75 N
AI M 55 1985 IgMK 2/86 21. 0 86 N
J J F 65 1979 IgMK 8/85 15.7 64 N
AN F 58 1983 IgMX 10/85 8.4 55 N
JR M 71 1987 IgMX 9/87 47. 4 94 N
AR M 51 1970 IgMK 9/87 32. 6 98 N
JS F 55 1983 IgGA 10/85 14. 4 72 N
MSm F 68 1983 IgAK 10/85 19. 6 64 N





Ig Iso = Ig isotype
WCC = total white cell count x 10®/I of 1st sample
Lymph = lymphocyte count (% of WCC)
Rx = Cytotoxic therapy at time of sampling
(Y = yes, N = never treated,
O = off treatment)
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TABLE 2.2
Characteristics of Clinical Stage B Patients








AB F 56 1979 IgAA 6/87 25. 1 74 O
MC F 88 1986 IgMA 2/86 40. 0 89 N
WC M 62 1984 IgGK 10/87 14.6 72 N
LC F 75 1984 IgMA 9/87 88. 0 96 N
MGr F 75 1982 IgMK 9/87 41. 7 96 N
LG F 75 1983 IgMA 6/87 53. 2 94 O
RH F 61 1983 IgMA 10/85 28. 0 81 O
PK M 73 1986 IgMA 3/86 180 92 N
AM M 62 1978 IgMA 11/85 67. 7 95 Y
IM M 64 1979 IgMK 11/85 36. 3 82 O
DN F 5 4 1977 IgAA 10/85 18. 8 73 N
RPa M 71 1982 IgMK 3/86 142 99 N
MS F 81 1985 IgGK 6/87 127 95 N
ASh M 36 1982 IgMK 1/86 11. 2 87 Y





Ig Iso = Ig isotype
WCC = total white cell count x 10'/I of 1st sample
Lymph = lymphocyte count (% WCC)
Rx = Cytotoxic therapy at time of sampling
(Y = yes, N = never treated,
O = off treatment)
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TABLE 2.3
Characteristics of Clinical Stage C Patients








LA M 4 8 1981 I gG K 12/86 28. 0 92 Y
CC F 64 1982 IgMK 11/85 5.8 45 Y
CD F 82 1984 IgMA 10/87 68. 0 94 N
TE M 66 1985 IgMK 6/87 17. 7 91 O
PM M 51 1982 IgMK 9/87 64. 7 97 Y
WM M 77 1985 IgMA 10/85 18. 0 81 N
RP M kO 1974 IgMK 11/85 157 97 Y
CP M 70 1980 IgMA 1/86 31. 7 99 Y
JSk M 53 1979 IgGK 8/85 17. 3 95 O
JSm M 63 1984 IgMA 8/87 28. 1 95 N
GS M 60 1980 IgMA 8/87 37. 1 90 O
MT F 65 1973 IgGK 8/87 155 97 N
JT M 56 1984 IgMA 7/87 16. 6 85 Y





Ig Iso = Ig isotype
WCC = total white cell count x lo'/I of 1st sample
Lymph = lymphocyte count (% WCC)
Rx = Cytotoxic therapy at time of sampling
(Y = yes, N = never treated,
O = off treatment)
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TABLE 2.4
The JS Monoclonal Antibody Panel Characterised by
Radioimmunoassay





44.3C6 15 1488.6 +/- 266.4
44.3C1 8 931.8 +/- 244.6
44.4B4 6 331.9 +/- 87.3
47.7B3 2 144.7 +/- 31.0
44.2A1 3 471.1 +/- 82.0
2H3.D6 3 206.9 +/- 36.3
47.5A2 8 480.3 +/- 167.3
2G5 1 166.8 +/- 34.7
DPF11 1 167.8 +/- 55.4
1B2 1 296.2 +/- 87.2
49.8B4 0 237.8 +/- 185-9
47.1B2 0 193-0 +/- 42.0
47.1D5 0 201.1 +/- 48.9
47.2B3 0 295.1 +/- 92.1
McAbs were positive for paraproteins when
binding was significantly greater than background.
Normal serum results are means of 50 individual
sera +/- standard deviation,
cpm = counts per minute












Sample 38 1: 10 3 0 0
Sample 38 neat H 0 0
Sample 53 Is 10 0 0 0
Sample 53 neat 0 5 6
All values refer to diameter of precipitation rings
in millimetres at 2tl hours.
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FIGURE 2.1
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FIGURE 2.2






















all results are means of duplicate wells.
background optical den3tv (culture medium only)- 0
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CALIBRATED NORMAL SERUM
IN PBS (ng/ml of IgG)
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figure 2.3
standard curve for iqm specific elisa assay
all results are means of dupucate wells.
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FIGURE 2.4
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FIGURE 2.5
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FIGURE 2.6
COMPARISON OF STANDARD CURVES FROM IgM ELI5A ASSAY
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PLATE 2.1
SDS-PAGE of Samples from Gel Filtration Eluate
Tracks 1, 3, and 5:
Track 2 shows single bands corresponding to IgM heavy and
light chains. Very faint band at 50000 may represent
IgG or IgA heavy chains.
Track 4 shows single band at 30000, corresponding to Ig
light chain, and several bands >50000 which would













Track 2: Pooled samples 36-40 (lmg/ml)
Track 4 Pooled samples 52-54 (lmg/ml)
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CHAPTER 3







£l-stage Idiotope specific ELISA assay
(as described in chapter 2.)
3.3 INTRODUCTION
In their original characterisation the reactivity of the
JS McAbs against 50 normal sera and 159 paraproteins was
determined by a solid phase radioimmunoassay (Walker et
al, 1987). Antibodies HH.3C6, ZU.3C1 and, k7.5A2 which
each reacted with 8 or more paraproteins, also showed the
highest binding to the normal sera (see table 2.k). For
the remaining antibodies, however, the correlation










panel and the reactivity with the normal sera was less
clear. For instance, antibody &7.2B3, which does not
react with any of the paraproteins, had a higher binding
to normal serum than antibody 2H3-D6 which reacts with 3
of the paraproteins (see table 2.H).
These findings could be due to the different expression
of specific V region associated epitopes by the B-cell
clones represented in normal serum Ig and the paraprotein
panel. However, an alternative explanation is that the
radioimmunoassay assay was not sensitive enough at low
levels to discriminate between antibodies with low
reactivity for normal serum and those with no significant
reactivity.
It was important, for the purposes of this investigation,
to compare the expression, in normal serum, of the
different epitopes recognised by the JS McAb panel. In
order to do so, a highly sensitive ELISA assay, capable
of detecting as little as 10ng/ml of a specific idiotope,
was developed. The assay was adapted from a 3~stage Ig
specific ELISA assay (Lems Van-Kan et al, 1983.) and was
first standardised using a purified preparation of the JS
paraprotein. The reactivity of the JS McAbs with pooled
human IgG, pooled human serum and 1U individual sera was
then tested using this assay.
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3-4 IDIOTOPE SPECIFIC ELISA ASSAY
The assay is shown diagramatically in figure 3-1.
Initial attempts to bind the JS McAbs directly to the
wells were unsatisfactory. This was overcome by the use
of goat anti-mouse Ig (adsorbed against human serum
proteins,) as a capture antibody. This increased the
chances of inter-species cross-reactions between
different Ig molecules so negative controls (PBS in place
of the human Ig at the third stage,) were included for
each JS McAb in each assay. The background optical
density (OD) rarely exceeded 0.1 units except for
antibodies 44.3C6 and 44.4B4 where backgrounds up to 0.40
were seen particularly if the blocking buffer was more
than 48 hours old.
Controls without mouse Ig but with the human Ig
preparation were also included. Some preparations of
human Ig did show significant binding to the goat
anti-mouse Ig capture antibody. In such cases the
binding in the absence of mouse monoclonal Ig was greater
than that seen with non-reacting antibodies in the panel.
This suggests that the binding sites available on the
goat anti-mouse Ig antibody are effectively saturated by
the mouse Ig thus preventing binding by human Ig.
Results were taken as positive when the difference
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between the observed result and the background for that
particular JS McAb exceeded 0.15 units of optical
density.
3.5 RESULTS
3-5-1 Binding of JS McAbs to JS Paraprotein
The assay was standardised using purified JS paraprotein
(gifted by Dr. J.A. Habeshaw). Figure 3-2 shows that the
assay was sensitive enough to detect binding in 10 out of
14 JS McAbs at lOng/ml of JS paraprotein and 13 out of 14
at lOOng/ml using the anti-Y antibody conjugate. All the
antibodies were strongly positive (ODs > 1.4,) with
lOOOng/ml of paraprotein.
The 4 antibodies which were negative at lOng/ml were
known to have relatively low affinity for the imraunogen
(Walker et al, 1987). The remaining antibodies all had
similar affinities for the JS paraprotein so their
binding patterns to normal Ig could be compared.
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3.5.2 Binding of JS McAbs to Pooled Normal IgG
Figure 3.3 shows the binding pattern using pooled normal
IgG diluted to 10ug/ml in PBS and the anti-Y antibody
conjugate. Higher concentrations of IgG gave markedly
increased background results. The strong binding to
monoclonal anti-K, anti-X and, antibody 19.3C1 confirm
the presence of polyclonal IgG. There is insignificant
binding of IgG to 7 of the JS McAbs (1B2, 2G5, DPF11,
19.8B1, 17. 1B2, 17-1D5 and. 17.2B3.) with all ODs <0.10.
The remaining 7 JS McAbs are split into 2 groups; H
antibodies (11.3C6, 11.3C1, Ixk.lXBlX and. 1 7.5A2.) show
strong binding to IgG (ODs >1.0,) while an intermediate
group of 3 antibodies (17.7B3. 11.2A1 and, 2H3-D6.) show
much weaker binding (ODs 0.31 - 0.15).
3.5.3 Binding of JS McAbs to Pooled Normal Serum
The pooled, calibrated serum contained 12.76 mg/ml of Ig
and was diluted in PBS to a final Ig concentration of
lOug/ml. The assay was performed using a polyvalent
detection antibody recognising all Ig isotypes and the
results are shown in figure 3-1. There are minor changes
in the relative affinities of different antibodies
compared to the results using pooled IgG but the overall
pattern of reactivity is similar with the same antibodies
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in the strong (ODs >0.48,) intermediate (ODs 0.15 -
0.21,) and, weak (ODs <0.07,) groups.
3.5.4 Binding of Selected JS McAbs to Individual
Normal Sera
The weak binding of pooled normal Ig to the intermediate
group of JS McAbs could have been a consequence of strong
expression of the relevant V region associated epitopes
by small numbers of individuals or to weak expression by
many individuals. To investigate this 14 individual sera
were obtained from samples which had been sent for a
routine virological screen and were all negative for
antibodies to common viruses. Each serum was diluted
1:1000 and tested in duplicate for binding to the
intermediate group of JS McAbs (47-7B3, 44.2A1 and
2H3.D6,) as well as 1 antibody (44.3C6,) which reacted
strongly with pooled Ig and 1 (47.1B2,) which did not
bind significantly.
The results are shown in table 3.1. None of the sera bind
significantly to 47.1B2 (ODs <0.09,) whereas all the sera
show strong binding to 44.3C6 with mean ODs from 0.49 -
0.73- Most of the sera do react with the intermediate
group of JS McAbs although serum 11 did not react
significantly with any of them in spite of reactivity
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with UH.3C6 and serum 3 did not react significantly with
2H3-D6.
The mean ODs of the binding to the different antibodies
were compared by Student's t test. There is no
significant difference between the means for antibodies
2H3-D6 and 47-7B3 although the mean OD for UH.2A1 is
higher than 2H3-D6 (p <0.01.) and U7.7B3 (P < 0.05). The
means of all these intermediate group antibodies are,
however, very significantly lower than the mean of
antibody UH.3C6 (p <0.001,) and higher than the mean of
k7.1B2 (p <0.001).
3.6 DISCUSSION
These results extend the original characterisation of the
JS McAbs (Walker et al, 1987,) by clearly sub-dividing
the public idiotopes into two groups which may be of
functional and practical significance. Thus the epitopes
recognised by the panel antibodies can be divided into
three distinct groups expressed by normal serum
immunoglobulin (table 3.2):-
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3.6.1 Private Determinants Recognised b.v JS McAbs
The 7 antibodies (2G5, DPF11, 1B2, H9.&BU, U7.1B2.
/17.1D5. and Z17.2B3. ) which do not react significantly
with normal Ig by ELISA or with the paraprotein panel by
radio-binding assay (Walker et al, 1987,) recognise
private determinants on the JS paraprotein. None of these
antibodies reacted with isolated JS heavy or light chains
suggesting that they recognise conformational
determinants which are dependent on 2 unrelated genes
(Vh and Vi , ) for their expression.
These antibodies are typical of anti-idiotypic antibodies
recognising private, antigen binding site related
determinants which characteristically arise by somatic
mutation (Rajewsky & Takemori, 1983).
3.6.2 Public Determinants Recognised bv JS McAbs
The k antibodies reacting with this group each reacted
with 6 or more paraproteins and include 3 antibodies
specific for lambda chain (UU.3C6, 44.3C1, and Ull.k&k, )
and 1 (Z17.5A2, ) specific for heavy chain (Walker et al,
1987). They each react strongly with the pooled normal Ig
preparations and antibody UU.3C6 reacts strongly with all
the individual sera.
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These determinants, which are obviously common to many
different B-cell clones, are likely to be framework
determinants characteristic of a major V gene sub-group
or variant constant region determinants. Analysis of the
primary structures of the JS and other paraproteins
expressing these determinants may be required to
characterise the antibodies further.
3.6.3 Restricted Public Determinants Recognised b.v
JS McAbs
The 3 antibodies reacting with these determinants each
react with 2 or 3 paraproteins and include 1 specific
for lambda chain (4-7. 7B3, ) and 2 which are specific for
heavy chain (Zi/l.2Al and 2H3-D6.) Their expression in
normal Ig is much reduced compared to the public
determinants.
These determinants are likely to be shared idiotopes
conserved by the immune system and expressed by small
numbers of B-cell clones. Their specificity for heavy or
light chain suggests that they may be products of single
V region genes. These features are characteristic of
regulatory idiotopes (Bona et al, 1987).
- 79 -
TABLE 3.1
Binding of Individual Normal Sera to Selected JS McAbs
JS McAb
Serum
44. 3C6 47.7B3 44.2A1 2H3.D6 47.1B2
1 0. 73 0. 29 0. 40 0. 35 0. 05
2 0. 66 0. 23 0. 42 0. 18 0. 02
3 0. 74. 0. 17 0. 24 0. 11 0. 03
4 0. 70 0. 47 0. 37 0. 27 0. 05
5 0. 67 0. 30 0. 33 0. 24 0. 01
6 0. 62 0. 17 0. 48 0. 23 0. 03
7 0. 62 0. 23 0. 30 0. 19 0. 06
8 0. 60 0. 25 0. 33 0. 21 0. 05
9 0. 63 0. 30 0. 48 0. 33 0. 09
10 0. 52 0. 18 0. 29 0. 20 0
11 0. 52 0. 14 0. 13 0. 08 0
12 0. 60 0. 19 0. 17 0. 16 0. 02
13 0. 49 0. 16 0. 23 0. 18 0. 04
14 0. 52 0. 24 0. 26 0. 19 0. 03
Mean 0. 616 0. 237 0. 316 0. 209 0. 034
SD 0. 081 0. 096 0. 107 0. 074 0. 025
All results are the means of duplicate wells and are
expressed in units of optical density. All background ODs
< 0.03
SD = standard deviation
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TABLE 3-2
VARIABLE REGION ASSOCIATED EPITOPES DEFINED BY
JS MONOCLONAL ANTIBODY PANEL:
Correlation of specificity for JS paraprotein
with expression in normal serum
Specificity Expression in
JS McAb for immunising normal serum
paraprotein by ELISA
Ml.3C6 Lambda Public
till. 3C6 Lambda Public
Ml. UBk Lambda Public
U7.7B3 Lambda Restricted
Ml. 2A1 Heavy Chain Restricted
2H3-D6 Heavy Chain Restricted
U7.5A2 Heavy Chain Public
2G5 Intact Ig Private
DPF11 Intact Ig Private
1B2 Intact Ig Private
49.8B4 Intact Ig Private
47.1B2 Intact Ig Private
tl7. 1D5 Intact Ig Private
47.2B3 Intact Ig Private
Public = optical density >0.5 by ELISA
Restricted = optical density <0.3 >0.1U by ELISA
private = optical density <0.08 by ELISA
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FIGURE 3.1
FOUR STAGE ELISA ASSAY
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FIGURE 3.3
BINDING OF POOLED NORMAL IqG TO JS MONOCLONAL
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FIGURE 3.4
BINDING OF NORMAL SERUM lq TO JS MONOCLONAL
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CHAPTER 4
REACTIVITY OF JS MONOCLONAL ANTIBODY PANEL WITH CHRONIC
LYMPHOCYTIC LEUKAEMIA CELLS
4.1 MATERIALS




Preparation of Cell Lysate
3-Stage Human Ig ELISA Assay
4-Stage Idiotope Specific ELISA Assay
4.3 INTRODUCTION
The reactivity of each JS McAb with cells from 42
patients with CLL was determined by indirect
immunoperoxidase on acetone fixed cytospin preparations
of PBMNC.
In most cases the staining pattern seen with a positive
JS McAb was identical to that seen with the tumour
specific anti-light chain antibody suggesting that the JS
McAbs were binding tumour specific Ig. There were,
however, a number of instances when the staining pattern
seen with JS McAbs was either very weak or was
qualitatively different from that seen with the
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anti-light chain antibody.
The JS antibody panel has not been extensively tested
against the complex range of proteins expressed by cells
although antibody 1B2 has been shown to cross-react with
an epitope expressed by human epithelial cells (J.A.
Habeshaw, personal communication). The existance of such
cross-reactions would not be surprising in view of
idiotypic diversity and, as a consequence, it was
necessary to demonstrate that the reactivity of JS McAbs
with CLL cells was specific for tumour Ig.
Characteristically CLL cells express low levels of
surface Ig but in vitro stimulation with phorbol esters
has been shown to increase Ig production and secretion in
most cases (Totterman et al, 1980 and, Gordon et al,
1984b). Thus reactivity of JS McAbs with tumour specific
Ig will be associated with increased cytoplasmic staining
of TPA stimulated cells by immunoperoxidase and, the
specificity of the reaction for tumour specific Ig can




4.4.1 JS McAb Binding to CLL Cells
In each immunoperoxidase run a single patient's cells
were tested against the complete JS McAb panel as well as
anti-K and anti-A antibodies (SAPU) and a negative
control (no primary antibody). The light chain specific
antibodies were a positive control for the presence of
monoclonal Ig and also a control for the non-specific
binding of mouse Ig. In addition, the 14 JS McAbs, which
were all ascites preparations raised in the same strain
of mice and, were all IgGl sub-class, acted as their own
negative controls for each other.
The number of cells reacting with each antibody was
assessed semi-quantitatively and patients were only
considered positive when the same population of cells
reacted with a JS McAb and the tumour specific anti-light
chain antibody. Sixteen patients reacted with at least 1
of the JS McAbs and 10 reacted with 2 or more but these
included a number of cases where the staining was weak or
of questionable specificity (table 4.1). Examples of the
various staining patterns seen are shown in plates 4.1 to
4. 10.
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4.4.1.1 Typical Staining Patterns
In plate 4.1 almost all the cells from patient CD are
positive with anti-X used as the primary antibody. The
granular pattern was typical of Ig staining in the
majority of CLLs and an identical pattern was seen with 4
of the JS McAbs including 44.3C6 (plate 4.2,) suggesting
that the JS McAbs are also reacting with tumour specific
Ig.
In a minority of CLLs cytoplasmic Ig forms crystalline
inclusion bodies (Guglielmi et al, 1982). For instance,
the majority of cells from patient LA contain
needle-like cytoplasmic inclusions reacting with anti-K.
Plate 4.3 shows the same pattern of reactivity with the
JS McAb 2H3.D6. Cells from another patient (HB) show
strong staining with anti-X with the occasional cell
containing a positively staining cytoplasmic block. The
same pattern is seen with the JS McAbs 44.3C6 and 44.4B4
(plate 4.4). In such cases there can be little doubt
about the specificity of the JS McAbs for tumour specific
Ig.
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4.4.1.2 Weak Staining Patterns
In a number of cases the staining patterns seen with JS
McAbs (particularly 44.2A1,) were similar to those seen
with tumour specific anti-light chain antibodies but were
very weak. For instance, cells from patient TE show
strong staining with anti-K (plate 4.5.) but much weaker
staining with antibody 44.2A1 although the granular
pattern is still visible (plate 4.6). Repeating the
immunoperoxidase with a more concentrated solution of
44.2A1 as the primary antibody was unhelpful because of
significant background staining. This was probably due to
non-specific binding of murine proteins in the ascites
preparation.
4.4.1.3 Questionable Staining Patterns
In a number of cases the staining patterns seen with JS
McAbs were qualitatively different from the tumour
specific anti-light chain antibodies. For instance cells
from patient MT show typical granular staining with
anti-K (plate 4.7,) but with 49.8B4 the staining pattern
is different with the majority of cells showing
discrete blocks of cytoplasmic staining (plate 4.8).
- 90 -
Plate U. 9 shows typical granular* staining of cells from
patient LQ with anti-X as the primary antibody. Plate
/i. 10, however, shows a weak diffuse deposition of the
reaction product with antibody li7 • 5A2. This pattern is
suggestive of non-specific binding but was seen in 5
cases with antibody U7-5A2.
li.Ur.2. JS McAb Binding to TPA Stimulated Cells
Fresh or frozen cells were available for TPA stimulation
from l/l of the 16 patients whose cells reacted with 1 or
more of the JS McAbs by immunoperoxidase. Cells from 5
patients who were negative with all the antibodies were
also tested. Those not available for further study were
patient RK whose cells were strongly positive with all
but one of the JS McAbs and, patient AS whose cells were
weakly positive with antibody 49.8B/1.
The cells were cultured in the presence of lOOng/ml of
TPA for 6 days after which the supernatants were
collected and stored. The TPA stimulated cells were
washed 3 times, resuspended at 2 x 10'/ml in RPMI and
cytospin preparations made as before. In 5 of the
patients the cells were E-depleted prior to culture.
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An MGG stain of unstimulated cells from patient PC (plate
4.11,) shows the majority of cells to be small round
lymphocytes with scanty cytoplasm and clumped nuclear
chromatin. Occasional cells have more prominent cytoplasm
and azurophilic granules. After TPA stimulation, cultures
contained cells of varying morphology (plate 4.12,)
ranging from small lymphocytes to large blast cells with
some plasmacytic features; eccentrically placed nuclei,
plentiful basophilic cytoplasm, a prominent Golgi area
and some cytoplasmic vacuoles.
The binding of the JS McAb panel to the TPA stimulated
cells was tested by indirect immunoperoxidase as
previously. All cases showed an increase in cytoplasmic
staining with the tumour specific anti-light chain
antibody (plates 4.13 and 4.14). Three patterns of
results with the JS McAbs were identified other than
those which were negative before and after stimulation:-
i) Positive unstimulated and stimulated cells
ii) Positive unstimulated but negative stimulated cells
iii) Negative unstimulated but positive stimulated cells
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Zl.il-. 2.1 Positive Unstimulated and Stimulated Cells
All available cases which were positive with the lambda
specific "public" antibodies, the "restricted public"
antibodies and, 2 out of 7 cases reacting with the heavy
chain specific "public" antibody (ZI7.5A2) showed an
increase in cytoplasmic reactivity with the JS McAb after
TPA stimulation (table U.2).
In contrast, out of 7 cases of "private" JS McAbs
reacting with unstimulated cells only 1 case (patient MT
with antibody ZJ.7.2B3,) showed staining of TPA stimulated
cells.
tl.U.2.2 Positive Unstimulated but Negative Stimulated
Cells
All 5 of the patients whose cells showed the diffuse
staining pattern with antibody /17-5A2 were studied and in
none of them did the TPA stimulated cells show
significant reactivity with this antibody. Similarly 5 of
the 7 patients whose cells had reacted with antibody
IX9.&BU and cells from patient LG which reacted with
ZI7.1B2 were studied and none of the TPA stimulated cells
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reacted with these antibodies.
In these cases it is likely that the reactivity of JS
McAbs with unstimulated cells is due to non-specific
binding or cross-reactivity with an epitope expressed by
a molecule other than Ig. However, the possibility that
TPA stimulation resulted in altered idiotype expression
by the tumour cells cannot be excluded.
4.4.2.3 Negative Unstimulated but Positive Stimulated
Cells.
In a number of instances TPA stimulated cells were
positive with antibodies when the unstimulated cells had
been negative (table it. 3). For instance, unstimulated
cells from patient AB were positive with 3 JS McAbs
(U7.7B3, 44.2A1 and, 47. 5A2) . The TPA stimulated cells
only reacted with 2 of these (47.7B3 and, 44.2A1,) but,
additionally, a further 6 antibodies (table 4.3). The
pattern of staining with these antibodies was
indistinguishable from that seen with anti-X (plates lx. 15
and 4.16).
Similarly unstimulated cells from patient PM were
negative for all the antibodies but a proportion of the
TPA stimulated cells reacted strongly with 5 of the JS
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McAbs. In 3 other instances TPA stimulated cells were
positive with antibodies when the unstimulated cells
were negative (patient LG with /J.4.3C1, MS with 4/J..2A1
and, CD with 47.7B3.)
tl.H. 3 Ig Secretion b.v CLL Cells
The Ig levels in the supernatants of TPA stimulated cells
were assayed using the 3-stage ELISA. All the samples
were done in duplicate and IgG, IgM, and IgA were
quantitated from standard curves as described in chapter
2. Kappa and lambda results were expressed as units of
optical density. Only 1 supernatant (patient LA,) did not
contain significant amounts of Ig. The results from the
other 18 culture supernatants are shown in table U.U.
Out of 111 PBMNC cultures only 2 supernatants (HB and PM)
contained monotypic Ig with a single isotype and a single
light chain. A further 3 (MS, MT, and RP) show a single
isotype and a marked predominance of the light chain
expressed by the tumour cells. The remaining 8
supernatants contained polyclonal Ig.
The 5 supernatants from E-depleted cultured cells include
U which contain monotypic Ig and one (RPa) with a single
isotype and both light chains.
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IX. IX. IX Binding of Secreted Ig to JS McAb Panel
The reactivity of Ig in culture supernatants with the JS
McAbs and murine anti-K and anti-X was assessed using the
/1-stage ELISA assay as described previously. Results were
considered positive when the difference between the
result and the background for that antibody was greater
than 0.15 units of optical density.
In supernatants containing monotypic Ig the assay was
only performed using the relevant anti-isotypic antibody
conjugates and all samples were done in duplicate.
In supernatants containing polyclonal Ig binding of
tumour specific Ig to a JS McAb could be demonstrated in
2 ways:-
i. Binding of secreted Ig to the anti-K and anti-X
murine monoclonal capture antibodies demonstrated
that the isotype corresponding to the tumour cell
phenotype had the same light chain restriction as
the tumour cells (figure IX. la).
ii. Secreted Ig binding a JS McAb was shown to have
the same isotype and light chain restriction as
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the tumour cells using the polyclonal goat
anti-isotype and anti-light chain antibody
conjugates (figure 4.1b).
In assays where antibody conjugates specific for both
light chains and all 3 isotypes were required the numbers
involved made it impractical to include duplicate
samples although inconclusive results were repeated in
duplicate. Furthermore, the detection of tumour specific
Id reacting with a JS McAb in such assays depended on
positive results with the relevant anti-isotypic and
anti-light chain antibodies so 2 separate results were
still required before a sample was considered positive.
In 7 out of 18 supernatants there was no significant
binding to any of the JS McAbs. The results of the 11
remaining cases are shown in tables 4.5 to 4.15 and can
be divided into 5 groups:-
i) Positive Supernatants, Stimulated and
Unstimulated Cells
ii) Negative Supernatants but Positive Stimulated and
Unstimulated Cells
iii) Positive Supernatants but Negative Stimulated
and Unstimulated Cells
iv) Negative Supernatants and Stimulated Cells but
Positive Unstimulated Cells
v) Negative Supernatants and Unstimulated Cells but
Positive Stimulated Cells
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4.4.4.1 Positive Supernatants, Stimulated and
Unstimulated Cells
In 18 instances the specificity of the cellular reactions
of JS McAbs with the unstimulated and stimulated cells
was confirmed by binding of secreted Id to the JS McAbs
in the ELISA (see tables 4. 5 to 4.13). Eight of these
involved the antibodies 44.2A1, 2H3.D6, or 47.5A2 and in
all these cases the reactivity was due to monotypic Ig
with the same isotype and light chain as the tumour
(tables 4.8 to 4.13).
There were a further 10 instances when supernatants from
lambda expressing tumours showed significant reactivity
with the lambda specific McAbs (tables 4.5 to 4.9). In 9
of these the reactivity could be confirmed as tumour Ig
specific on the basis of isotype matching and/or the
identification of monotypic Ig in the supernatant. In
patient LG the binding of 44.4B4 to IgM in the
supernatant could not be confirmed due to a
cross-reaction between 44.4B4 and one batch of goat
anti-human IgM conjugate.
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U. IX. U . 2 Negative Supernatants but Positive Stimulated and
Unstimulated Cells
In 3 instances JS McAbs which reacted with stimulated and
unstimulated cells did not react with secreted Ig despite
the demonstration of monotypic Ig in the culture
supernatants. These involved patient AB whose cells
reacted with 47.7B3 and HU.2A1 (table H.llX,) and patient
MT whose cells reacted with 47.2B3.
U. H. IX . 3 Positive Supernatant but Negative Stimulated
and Unstimulated Cells
Significant binding of secreted Ig to the JS McAbs in the
absence of cellular reactivity only occurred in culture
supernatants containing polyclonal Ig and mainly with the
public determinants recognised by 44.3C6, UU.3C1, UU-.txEH,
and IX7.5A2. The first 3 are lambda specific antibodies
but reacted with polyclonal IgG in supernatants from
kappa and lambda expressing tumours (tables il.10, IX. 11,
lX.13, IX.IU and IX. 15). Similarly antibody Lx 7.5A2 reacted
with polyclonal IgG in 5 supernatants from IgM and IgA
expressing tumours in the absence of cellular reactivity.
The binding of secreted Ig to 47.5A2 detected by the
anti-light chain antibodies was much weaker than with the
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anti-Y. Light chain restriction was only apparent in 1 of
these cases (table 5-15.) but this may be a reflection of
the normal 2:1 kappa:lambda ratio in humans.
In two patients with IgG expressing tumours there was
weak binding of secreted IgG to the "restricted public"
antibody 44.2A1 (tables 4.12 and 4.13.) but, in both
cases the light chain specific antibodies were negative.
4.4.4.4 Negative Supernatants and Stimulated Cells but.
Positive Unstimulated Cells
In all 11 instances in which JS McAb reactivity with
unstimulated cells was lost after TPA stimulation (table
4.2,) secreted Ig was unreactive with the antibodies by
ELISA.
Antibody 49.8B4 did not react with secreted Ig in
culture supernatants from 5 patients whose cells reacted
with the antibody even though all of them contained
monotypic Ig. Similarly, secreted tumour specific Ig from
LG cells did not react with antibody 47.1B2 by ELISA
(table 4.6).
Secreted tumour specific Ig did not react with 47.5A2 in
any of the 5 cases where unstimulated cells had shown
diffuse reactivity with the antibody (plates 4.9 and
4.10). In 3 of these cases, however, secreted polyclonal
IgG did bind to 47-5A2.
4.4.4.5 Negative Supernatants and Unstimulated Cells but
Positive Stimulated Cells
There were 15 instances in which TPA stimulated cells had
reacted with JS McAbs when the unstimulated cells had
been negative (table 4.3.) but in none of them did the
culture supernatants react with the antibodies involved.
These results could be explained either by antigenic
differences between secretory and cytoplasmic Ig or by
reactivity of the JS McAbs with epitopes expressed by
molecules other than Ig.
In order to investigate this further cell lysates were
prepared from TPA stimulated cells and the extract
tested for reactivity with the JS McAbs using the ELISA
system.
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4.4.5 Binding of Cytoplasmic Ig to the JS McAb Panel
Fresh or frozen cells were obtained from the 5 patients
in whom JS McAbs had reacted with TPA stimulated cells
but not with unstimulated cells or with secreted Ig
(table 4.3). In addition cells from patient MT were
studied as cellular reactivity with antibody 47.2B3
before and after TPA stimulation could not be confirmed
as specific by the ELISA.
Bulk cultures (100 xlO' cells in lOOmls culture medium,)
were stimulated with TPA at lOOng/ml. After 6 days the
cells were harvested, washed x3 in RPMI and the lysates
prepared as described in the methods. The Ig content of
each preparation was measured by the 3-stage ELISA using
serial dilutions of calibrated serum in PBS containing
1% NP-40 as the standards. Monotypic Ig was obtained from
all 6 cases (table 4.16).
The lysates were then tested for reactivity with the JS
McAbs using the 4-stage ELISA with the anti-isotypic
antibody conjugate appropriate for each sample. Cell
lysates from patients AB and PM, whose TPA stimulated
cells had reacted with multiple JS McAbs, were tested
against the entire JS McAb panel except for antibody
47-5A2. The sample from patient PM showed weak binding
to a number of antibodies including anti-X and the lambda
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specific JS McAbs (table 4.17). This is unlikely to
represent specific binding as the sample contained
monotypic IgMtc by the 3-stage ELISA (table 4.16).
The remaining samples were only tested against the
antibody in question plus a JS McAb known to react with
tumour specific Ig or anti-light chain antibodies as
positive controls (table 4.17). The results show that
none of the cases in which JS McAbs react with TPA
stimulated cells but not unstimulated cells or secreted
Ig is due to reactivity with cytoplasmic Ig. The positive
staining by immunoperoxidase in these cases must be due




Indirect immunoperoxidase is a highly sensitive technique
for demonstrating antibody/antigen complexes in cells and
there was no reason to doubt the specificity of the
results obtained with the JS McAbs on cytospin
preparations of CLL cells in the majority of cases.
There were, however, a number of cases in which the
staining patterns seen with a JS McAb were qualitatively
different from those seen with the tumour specific
anti-light chain antibody. It was therefore necessary to
demonstrate that the JS McAbs were reacting with tumour
specific Ig.
A simple method of doing this would be to demonstrate
loss of JS McAb binding in the presence of high
concentrations of the JS paraprotein but this approach
was rejected for 2 reasons.
First, the potential blocking ability of the JS
paraprotein is dependent on the paratope of a JS McAb
recognising an epitope shared by the CLL and JS
idiotypes. However, the JS McAbs were selected by virtue
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of affinity for the JS paraprotein V region and it is
just as likely that the JS paratope recognises an
idiotope expressed by a JS McAb. In that case it would be
possible for the paratope of the JS McAb to continue to
bind to an idiotope expressed by the CLL Id in spite of
the presence of excess JS paraprotein.
Secondly, monoclonal antibodies recognise epitopes rather
than antigens so the ability of the JS paraprotein to
block a JS McAb binding does not demonstrate specificity
for tumour Ig as the epitope recognised may be expressed
by other molecules.
A more direct method of demonstrating specificity would
be to stimulate Ig production by CLL cells in vitro using
a culture medium deficient in an essential amino acid
(for instance methionine,) and to provide that amino acid
labelled with a radio-active isotope such as 1 'Sulphur.
Ig molecules synthesised by the cells would incorporate
the label and could be used as a probe to detect binding
to the JS McAbs in a solid phase radioimmunoassay or by
Western blotting.
Preliminary studies demonstrated that TPA was highly
effective at inducing Ig secretion. However, the presence
of polyclonal Ig in many of the culture supernatants
could result in false positive results because of
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radio-labelled polyclonal Ig. This problem could be
circumvented using the il-stage ELISA assay because it was
possible to demonstrate that the Ig molecules reacting
with a particular JS McAb were restricted to the same
isotype and light chain as the tumour Id even when the
culture supernatant contained polyclonal Ig.
JS McAbs reacted with unstimulated CLL cells in 1X7
instances. In 32 of these the reactivity of the JS McAbs
for secreted Ig was tested by ELISA and in 18 cases the
cellular reactions were confirmed as specific for Ig.
The number of cellular reactions which were shown not to
be Ig specific (table ix. 18) demonstrate the importance of
using such a method to prove specificity.
IX. 5 • 1 False Positive Results
There were 1H instances when unstimulated CLL cells
reacted with JS McAbs by indirect immunoperoxidase but
secreted tumour specific Ig did not bind to the same
antibodies in the ELISA.
Five of these involved antibody U7.5A2 which reacts with
a public idiotope commonly expressed by IgG (see chapters
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2 and 3). In 2 patients with IgG expressing tumours
47-5A2 reacted specifically with cells and secreted Ig
(table 4.15 and 4.16,) but the weak, diffuse staining
pattern seen with 5 other patients was not specific for
tumour Ig, A similar staining pattern was seen with the
Glm(f) allotype specific antibody 49.3C1 in 1 case (table
4.10,) and it is probable that the diffuse staining in
these cases is due to McAb reactivity with polyclonal IgG
bound to the cells by Fc receptors (Stevenson et al,
1981).
Most of the other false positive results involved
antibody 49.8B4 which reacted with unstimulated cells
from 7 patients but, in the 5 of these who could be
studied further, 49.8B4 was unreactive with TPA
stimulated cells or secreted Ig. In these cases and also
that of antibody 47.1B2 with cells from patient LG the
reactivity of the JS McAb with unstimulated cells was
lost after TPA stimulation suggesting that the reactions
were due to non-specific binding or the determinant
involved had been lost from the cell surface and not
re-synthesised during culture.
In 3 instances (cells from patient AB with antibodies
47.7B3 and 44.2A1 and cells from patient MT and antibody
47.2B3,) JS McAbs reacted with both stimulated and
unstimulated cells but not with secreted Ig. Cytoplasmic
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Ig was extracted from TPA stimulated cells from both
these patients but this was also negative for the JS
McAbs by ELISA demonstrating that the JS McAbs were not
reacting with cellular Ig.
In addition to these false positive results there were 1U
instances when TPA stimulated cells reacted with JS McAbs
when the unstimulated cells had been negative. In all
these cases cytoplasmic Ig from the positive cells was
unreactive with the JS McAbs by ELISA suggesting that TPA
had induced the synthesis of a molecule expressing a
cross-reacting epitope.
In most cases which were subsequently shown to be false
positives, the cellular reactions were quantitatively or
qualitatively different from those seen with the tumour
specific anti-light chain antibody.
A great deal of effort would be required to identify the
cross-reacting determinants involved in false positive
results and this was not considered necessary for the
purposes of this investigation. Preliminary
characterisation might be to run cell lysates in
SDS-PAGE and agarose iso-electric focussing and to
determine the molecular weight and iso-electric points of
the molecules that the JS McAbs react with by Western
blotting.
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4.5*2 True Positive Results
The cellular reactions shown not to be specific for Ig
have been excluded from tables 4. 19 and 4.20 which show
the reactivity of the JS McAbs with tumour specific Ig in
lambda and kappa expressing CLLs. The only results which
have not been confirmed as specific for secreted Ig by
ELISA are those of patients RK and LA.
Patient RK's cells react with all but one of the JS McAbs
with a staining pattern similar to that seen with anti-X
suggesting that the reaction is specific for Ig. Assuming
this is so then either the tumour idiotype is very
similar to that of the original immunogen or it has
antigen binding specificity for an epitope expressed by
mouse Ig. The latter possibility is reduced by the
negative reactions with with anti-K and antibody DPF11.
Unfortunately, patient RK died shortly after diagnosis
before any cells had been cryopreserved and could not be
investigated further.
This finding could be of great interest as the chances
of 2 randomly selected paraproteins having almost
identical idiotypes is extremely small and it is
therefore possible that the 2 tumours shared a common
immunoregulatory defect associated with the expression of
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certain idiotypic determinants. However, a question mark
must remain over the results as the specificity of the
reactions for tumour Ig have not been proven and the
possibility of the tumour Id reacting with a murine Ig
epitope cannot be excluded.
Patient LA's cells contain crystalline inclusion bodies
reacting with anti-K strongly suggesting that the
reaction with antibody 2H3.D6 (plate H.3) is also
specific for tumour Ig.
In 2 patients (LA and CD,) positive for 2H3-D6 there are
minor populations of cells (5~10%) reacting with antibody
UH.2A1. In patient LA the kk.2A1 positive cells show the
characteristic cytoplasmic staining and are thus part of
the malignant clone. In patient CD secreted IgMX reacts
with UU.2A1 and it is therefore highly likely that the
cells staining with the antibody are also part of the
malignant clone.
Patient LA has been followed up over a 2 year period
during which the populations of cells expressing these
idiotopes have remained static.
In the remaining patients the population of cell staining
with the JS McAbs is always comparable to those positive




in proportion cannot be assessed
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table u.l
Reactivity of Cells from 1x2 Cases of CLL with JS
McAb Panel by Indirect Immunoperoxidase
Antibody Postive Weak Questionable
Cases Staining Staining
Ixlx. 3C6 6 0 0
iXk.3C1 3 0 0
ktl. tiBk IX 0 0
1x7.7B3 2 1 0
UU. 2A1 IX 3 0
2H3 • E>6 6 1 0
1X7. 5A2 8 5 5
2G5 1 0 0
DPF11 0 0 0
1B2 1 0 0
U9.&BU 7 IX 6
IX 7. 1B2 2 1 0
IX7. 1D5 1 0 0
1X7. 2B3 2 0 0
Positive cases = Number of cases in which the same
population of cells stained with tumour specific
anti-light chain antibody and JS McAb.
Weak staining = Number of cases in which staining
pattern seen with JS McAb much weaker than that of
tumour specific anti-light chain antibody.
Questionable staining = Number of cases in which staining
pattern seen with JS McAb was qualitatively different
from that seen with tumour specific light chain antibody.
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TABLE U.2
Reactivity of JS McAbs with TPA Stimulated CLL
Cells by Immunoperoxidase
Antibody No. Cases Positive Negative
UU.3C6 5 5 0
Ml. 3C1 2 2 0
Ml. HBtl 3 3 0
U7.7B3 1 1 0
Ml. 2A1 3 3 0
2H3.D6 U ll 0
U7.5A2 7 2 5
U9.&BH 5 0 5
U7.1B2 1 0 1
H7•2B3 1 1 0
No. cases = Number of cases in which PBMNC positive
with 1 or more JS McAbs were available for TPA
stimulation studies
Positive = Number of cases in which JS McAb reacted
with unstimulated and TPA stimulated cells
Negative = Number of cases in which JS McAb reacted with
unstimulated but not TPA stimulated cells
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TABLE H.3
Reactivity of JS McAbs with TPA Stimulated CLL Cells in
the Absence of Reactivity with Unstimulated Cells by
Immunoperoxidase
Antibody Patient









+ - JS McAb reacting with TPA stimulated cells but not
with unstimulated cells from same patient.
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TABLE ll.il
Ig Levels in TPA Stimulated Peripheral Blood Culture
Supernatants from 18 Cases of CLL Assayed
by 3-Stage ELISA
Patient Isotype IgM IgG IgA Kappa Lambda
ng/ml ng/ml ng/ml OD OD
HB IgMA 700 <16 <16 oo 1. 68
PM IgMK 8000 <16 <16 >2 0. 10
MS IgGK <16 130 <16 1. 67 0. 21
MT IgGK <16 ao <16 0. 80 0. 17
RP IgMK 92 <16 <16 1. 03 0. 26
CD IgMA >2000 >2000 50 1. 20 >2
PC IgMA 1150 310 110 o. 7a >2
LG IgMA &U 18 <16 o. a3 i. ai
AD IgG A <16 250 <16 0. 68 1. 01
MSm IgAK <16 57 13 0. 85 1. 22
AB IgA A <16 110 28 o. a9 0. 88
TE IgMK 120 135 76 1. 15 1. 02
MG IgMK 620 750 520 1. 70 >2
MGr IgMK 8a <16 <16 o. as 0. 08
JT IgMA 3800 <16 <16 0. 02 >2
GS IgMA 1100 <16 <16 0. 02 >2
AN IgMX aa <16 <16 0. 08 0. 35
RPa IgMK 275 <16 <16 0. 58 0. 17
Isotype = Tumour specific Ig detected by immunocytochemistry
OD = Optical Density
All results are means of duplicate wells.
MGr, JT, GS, AN, RPa cultured after E-depletion.
- 115 -
TABLE 4.5
Reactivity of JS McAbs with Cells and













































Culture supernatant contained IgMA (table 4.4)
CELLS = number of cells)
reacting with McAb on >
cytospin preparations >
by immunoperoxidase >
before and after TPA }
stimulation
- = negative ND = not done
►/- = <1% positive w = weak
+ = 1-20% positive D = diffuse
++ = 20-80% positive staining
= >80% positive pattern
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using




Reactivity of JS McAbs with Cells and


































































0. 01 0 ND ND
o. oa 0 ND ND
0 0 ND ND
o. oa 0 0 HOO
0. 02 0 ND ND
0. 01 0 ND ND
0 0 ND ND
Tumour phenotype: IgMA
Culture supernatant contained IgM and IgG (Table a.a)
CELLS = number of cells)
reacting with McAb on >
cytospin preparations >
by immunoperoxidase >
before and after TPA >
stimulation
= negative ND = not done
i-/- = <1% positive w = weak
+ = 1-20% positive D = diffuse
++ = 20-80% positive staining
>- + + = >80% positive pattern
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using
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Culture supernatant contained IgMA (table 4.4)
CELLS = number of cells) - = negative ND = not done
reacting with McAb on > +/- = <1% positive w = weak
cytospin preparations > + = 1-20% positive D = diffuse
by immunoperoxidase ) + + = 20-80% positive staining
before and after TPA > + + + = >80% positive pattern
stimulation
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using
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Culture supernatant contained IgM, IgG and IgA (table U.U)
CELLS = number of cells) - = negative ND = not done
reacting with McAb on } +/- = <1% positive w = weak
cytospin preparations > + = 1-20% positive D = diffuse
by immunoperoxidase > = 20-80% positive staining
before and after TPA } = >80% positive pattern
stimulation
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using
isotype and light chain specific ELISA assays.
Positive results underlined. Anti-a not tested
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TABLE 4.9
Reactivity of JS McAbs with Cells and
Secreted Ig from Patient PC
CELLS SUPERNATANT
McAb
Unstim TPA IgM IgG
Stim
Anti-K +/- +/- 0 0. 71
Anti-A + + + 0. 31 0. 21
1X9. 3C1 +/- +/- 0 0. 60
IXlX. 3C6 + + + + -+- + o. 46 0
IXIX. 3C1 + + + 0.46 0
44.4B4 - - 0. 02 0. 04
1X7. 7B3 — — 0 0
IXIX. 2A1 0 0
2H3.D6 + + + 0. 91 0. 01
1X7 ■ 5A2 + +w — 0 0. 12
2G5 _ 0. 06 0
DPF11 - - 0 0. 01
1B2 - - 0. 07 0
U9. 8BIX - - 0 0
1X7. 1B2 - - 0. 08 0
1X7. 105 - - 0. 08 0
1X7. 2B3 — — 0. 08 0
Tumour phenotype: IgMA
Culture supernatant contained IgM, IgG and IgA (table 4.4)
CELLS = number of cells > — = negative ND = not done
reacting with McAb on > +/- = <1% positive w weak
cytospin preparations > + = 1-20% positive D diffuse
by immunoperoxidase > + -t- = 20-80% positive staining
before and after TPA > + + + = >80% positive pattern
stimulation
SUPERNATANT = Reactivity (optical density minus background.)
of secreted Ig from TPA stimulated cultures with McAb using
isotype and light chain specific ELISA assays.
Positive results underlined. Anti-a not tested
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TABLE U.10
Reactivity of JS McAbs with Cells and












+ + +wD ++wD
0.5a 1.67 1.03
0.11 1.32 0.38






0.07 >2 0.02 >2 0.09
0.12 >2 0.05 >2 0.01
0.10 1.21 ND 1.37 0




-t- + + +
+ + +wD + + +wD
1.87 0.05 1.85 0.02 0.01
0.10 0.05 0.08 0.07 0









0 0.02 ND ND ND
0 0 ND ND ND
0 0 ND ND ND
0.10 0.03 0.05 0 0.02
0.03 0.03 ND ND ND
0 0 ND ND ND
o.io o.oa o.o6 0.03 o
Tumour phenotype: IgMic
Culture supernatant contained IgM, IgG and IgA (table a.a)
CELLS = number of cells) - = negative ND = not done
reacting with McAb on } +/- = <1% positive w = weak
cytospin preparations } + = 1-20% positive D = diffuse
by immunoperoxidase > + +■ = 20-80% positive staining
before and after TPA > -»• + + = >80% positive pattern
stimulation
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using




Reactivity of JS McAbs with Cells and










+ + + •+- 0.27 1.32 0.30
0.06 0.71 0.28





- 0 0.61 0.03 0.60 0.13
0 0.29 0.01 0.32 0.11
0.02 0.24 ND 0.13 0.07




+ +w + +
+ +W + + +
++wD +++wD
0.31 0 0.21 0.04 0.07
0.34 0 0.43 0.12 0.10









0.08 0.10 ND ND 0
0.06 0.08 ND ND 0.01
0.04 0.10 ND ND 0.01
0 0 0.05 0.01 0.11
0 0 0.020 0
0.06 0.11 ND ND 0
0.09 0.10 ND ND 0
Tumour phenotype: IgMK
Culture supernatant contained IgM, IgG and IgA (table 4.4)
CELLS = number of cells) - = negative ND = not done
reacting with McAb on } +/- = <1% positive w = weak
cytospin preparations } + = 1-20% positive D = diffuse
by immunoperoxidase ) + + = 20-80% positive staining
before and after TPA > + + -»- = >80% positive pattern
stimulation
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using




Reactivity of JS McAbs with Cells and





















- 0 0 0
0 0 0.03
0.03 0.02 0


























Culture supernatant contained IgGn+A (table il.il)
CELLS = number of cells) - = negative ND = not done
reacting with McAb on > +/- - <1% positive w = weak
cytospin preparations > + = 1-20% positive D = diffuse
by immunoperoxidase > + + = 20-80% positive staining
before and after TPA > + + + = >80% positive pattern
stimulation
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using




Reactivity of JS McAbs with Cells and



















- 0.03 0.82 1.47
0.05 0.41 0.76
























Culture supernatant contained IgGA+K (table 4.4)
CELLS = number of cells)
reacting with McAb on >
cytospin preparations >
by immunoperoxidase }
before and after TPA >
stimulation
- = negative ND = not done
+/- = <1% positive w = weak
+ = 1-20% positive D = diffuse
+ + = 20-80% positive staining
+ + -H = >80% positive pattern
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using




Reactivity of JS McAbs with Cells and




















- + + +W
+ +W + +
0 0.U5 0.88 0.03
0 0.09 0.36 0.02
o. on o o.05 o.on




+ +W + + +w
— + + +
+ +w -
0 0 0.08 0.03
0 0 0.13 0.02









— + + +
— + +
— + +
0 0 0 0
0 0 0 0
0 0 0.03 0
0 0 0.05 0.05
0 0 0.03 0.05
0.01 0 0.07 0.02
0 0 0.02 0.01
Tumour phenotype: IgAX
Culture supernatant contained IgG and IgA (table 4.4)
CELLS = number of cells) - = negative ND = not done
reacting with McAb on > +/- = <1% positive w = weak
cytospin preparations > + = 1-20% positive D = diffuse
by immunoperoxidase > + + = 20-80% positive staining
before and after TPA > + + + = >80% positive pattern
stimulation
SUPERNATANT = Reactivity (optical density minus background,)
of secreted Ig from TPA stimulated cultures with McAb using




Reactivity of JS McAbs with Cells and










































0. 02 0. 07 0 0. 08
0. 04 0. 11 0 0. 12









0 0. 03 0. 02 0. 06
0 0. 04 0. 08 0. 02
0 0. 04 0. 02 0. 03
0. 01 0. 03 0 0. 08
0 0. 03 0. 01 0. 03
0 0. 04 0. 01 0. 02
0 0. 04 0. 02 0. 01
IgG and IgA (table 4.4)
Tumour phenotype: IgAic
CELLS = number of cells)
reacting with McAb on >
cytospin preparations >
by immunoperoxidase >
before and after TPA >
stimulation
- = negative ND = not done
+/- = <1% positive w =» weak
+ = 1-20% positive D = diffuse
+ + = 20-80% positive staining
+ + + = >80% positive pattern
SUPERNATANT = Reactivity (optical density minus background.)
of secreted Ig from TPA stimulated cultures with McAb using




Ig Levels in Lysates from TPA Stimulated CLL Cells











PM IgMx 440 <16 <16 0. 45 0. 04
AB IgA A <16 <16 220 0. 08 0. 25
LG IgMA 200 <16 <16 0. 06 0. 53
MS IgGx <16 30 <16 0. 33 0. 05
CD IgMA 84 <16 <16 0 0. 93
MT IgGn <16 42 <16 0. 29 0. 06
Isotype = Tumour specific Ig by immunocytochemistry
All results are means of duplicate wells
OD = optical density
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TABLE 4.17
Reactivity of JS McAbs with Cytoplasmic Ig from
TPA Stimulated CLL Cells by 4-Stage ELISA
Antibody
Patient
AB PM CD LG MS MT
Anti-K
Anti-X
0 1.87 0.05 ND ND 0-31





0 0.18 *1.78 *0.77





















Results (optical density minus background,) are means
of duplicate wells.
♦signifies JS McAbs reacting with tumour specific Ig
used as positive controls.
ND = not done
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TABLE 4.18
Patterns of Reactivity of 14 JS McAbs with Cells






+ve +ve +ve 18
+ve +ve -ve 3
+ve -ve -ve 11
-ve +ve -ve 14
-ve -ve -ve 200
Unstimulated Cells = peripheral blood cells from CLL patients
TPA Stim. Cells = TPA stimulated cells from same patients
+ve = reactivity with JS McAb by immunoperoxidase
-ve = no reactivity with JS McAb
Secreted Id = tumour specific Ig secreted by TPA stimulated
cells in vitro
+ve = binding of secreted Id to JS McAb detected by ELISA
-ve = no binding by ELISA
No. = number of instances in which a JS McAb
reacted with cells and secreted Ig from
a single CLL in the pattern shown.
Six tests not performed.
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TABLE 4.19
Reactivity of JS McAbs with Tumour Idiotype in 21 Cases
of Lambda Expressing CLLs by Immunoperoxidase
JS McAb
Patient
























heavy chain specific determinants
conformational determinants
negative
<1% cells positive +
1-20% cells positive w





Reactivity of JS McAbs with Tumour Idiotype in 21 Cases
of Kappa Expressing CLLs
Patient
JS McAb
TE MG LA MS





IX7. 7B3 - - -
IXk. 2A1 + +w + +w - +w
HC 2H3-D6 + +w — + + + + +
IX7. 5A2 - — + + -
2G5 - - -
DPF11 - - -
1B2 - - -
Con IX9.&BIX - - -
IX 7- 1B2 - - -
1X7. 1D5 - - -
1X7. 2B3 - - -
17 patients negative with all antibodies.
X = lambda specific determinants
HC = heavy chain specific determinants
Con = conformational determinants
- = negative ++ = 20-80% cells positive
+/- = <1% cells positive +++ = >80% cells positive
+ = 1-20% cells positive w = weak reaction
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FIGURE 4.1
METHODS OF PROVING MONOCLONALITY OF |q IU
CULTURE SUPERNATANTS USING 4 STAGE ELISA
















POLYCLONALGOAT ANTI-HUMAN Ig (KAPPA ORSAbaSED
HUMAN la IN CULTURE
SUPERNATANT
lEj^QNOCLONAL ANTIBODY
POLYCLONAL GOAT ANTI-MOUSE Ig
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PLATE U.1
Cells from patient CD reacting with anti-X by
immunoperoxidase. Granular reactivity typical
of immunoglobulin. (xl600)
PLATE U.2
Cells from patient CD showing similar pattern of




«?1, *• v ,
, . c --
/- „ ^ s




Immunoperoxidase of cells from patient LA with





Iranunoperoxidase of cells from patient HB with
JS McAb tiH.kBU. Occasional cell showing block






Immunoperoxidase of cells from patient TE with
Anti-K. (xl600)
PLATE k.6
Immunoperoxidase of cells from patient TE with
JS McAb HU.2A1. Much weaker staining than with





Immunoperoxidase of cells from patient MT with
anti-K. (xl600)
PLATE U.8
Immunoperoxidase of cells from patient MT with
JS McAb U9.8Bk showing different pattern of
reactivity from anti-K. (xl600)
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PLATE tl. 9
Inununoperoxidase of cells from patient LG with
anti-X. (x!600)
PLATE U.10
Immunoperoxidase of cells from patient LG with





MQQ stain of cells from patient PC. Mostly small
round lymphocytes with scanty cytoplasm. (xl600)
PLATE a.12






MQQ stain of cells from patient PC after TPA
stimulation. Majority of cells have undergone




Immunoperoxidase of unstimulated cells from patient





Immunoperoxidase of TPA stimulated cells from




Immunoperoxidase of TPA stimulated cells from




- M ♦ W
%
Immunoperoxidase of TPA
patient AB with JS McAb






IMMUNOGLOBULIN SECRETION BY PERIPHERAL BLOOD CULTURES
FROM CLL PATIENTS
5.1 MATERIALS




3-Stage Ig ELISA Assay
5.3 INTRODUCTION
In the preceding chapter, the majority of TPA stimulated
PBMNC cultures from CLL patients were found to contain
polyclonal Ig even though most cultures contained less
than 1% of cells expressing the opposite Ig light chain
to the leukaemic clone (chapter 4). This was contrary to
published experience (Gordon et al, 1984b, ) in which only
monotypic, tumour specific Ig was detected using a
similar ELISA assay sensitive to lOng/ml.
In vitro Ig secretion by normal B-cells in response to
phorbol esters is dependent on helper T-cell factors
(Ralph & Kishimoto, 1982 and, Sugawara, 1982). In order
to investigate whether autologous T-cells contributed to
the production of polyclonal Ig in CLL cultures 15 cases
were studied before and after E-depletion.
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5.4 RESULTS
The patients studied included all clinical stages (3
stage A, 6 stage B, and 6 stage C). Ten had IgM and 5 had
IgG expressing tumours.
The number of T-cells before and after E-depletion was
assessed by immunoperoxidase studies on cytospin
preparations using monoclonal antibodies against the CD3,
CD4, and CD8 antigens (SAPU). A minimum of five hundred
cells were counted and the percentage positive with each
antibody is shown in table 5.1.
Ig levels in culture supernatants were measured using the
3-stage ELISA assay described previously. The difference
in mean ODs of samples analysed in the same assay was
analysed using Student's t test.
The supernatants were divided into 4 groups depending on
the Ig levels in PBMNC cultures. Only 4 samples, (group
1,) showed no significant increase in Ig levels after TPA
stimulation. The remaining supernatants were divided into
those containing polyclonal Ig with multiple isotypes
(group 2,) those with polyclonal Ig but a single isotype
(group 3.) and those containing monoclonal Ig (group 4).
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5.4.1 Group 1: No Change in Ig Secretion
In 4 cases there was no significant increase in Ig levels
in the TPA stimulated cultures compared to control
cultures containing no mitogen (Table 5-2). This group
included 1 IgM and 3 IgG expressing tumours and
patients with all clinical stages.
Two supernatants (from patients AR and JSk,) contained a
single isotype but both light chains while the other 2
(from JS and WC,) both IgG expressing tumours, contained
all three isotypes including high levels of IgG.
In all k cases Ig levels in the E-depleted cultures
(Table 5-3.) were reduced compared to PBMNC cultures.
Control and TPA stimulated E-depleted culture
supernatants from AR were negative for IgG, IgM, and IgA
but reacted weakly with anti-K in keeping with the known
ability of unstimulated CLL cells to secrete free light
chains in vitro (Gordon et al, 1984b).
TPA stimulated, E-depleted cultures from patient JSk
(whose tumour expressed IgGn,) contained small amounts of
IgG and IgM and were positive for kappa but not lambda.
The mean OD for IgG in the TPA stimulated culture was
significantly greater (p <0.01,) than in the control
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cultures whereas the IgM levels were not significantly
different. These results suggest that TPA stimulation
resulted in the secretion of small amount of tumour Id.
A similar effect in PBMNC cultures would be masked by
the presence of polyclonal IgG.
In supernatants from patients JS and WC, who had IgG
expressing tumours, there was a marked reduction of
polyclonal Ig production after E-depletion but there was
no significant difference between control and TPA
stimulated Ig levels. The supernatant from patient JS
contained polyclonal IgG while patient WC's contained
light chains only.
5-4.2 Group 2: Polyclonal Ig with More than
One Isotype
In 4 supernatants from PBMNC cultures TPA stimulation
resulted in increased Ig secretion over control cultures
but more than one isotype was present (table 5-4). All 4
tumours expressed IgM and the patients were all stage A
or B.
In 3 patients (JR, MGr, and LG,) there was a significant
increase in IgM but not IgG or IgA in PBMNC cultures
after TPA stimulation. This was almost certainly due to
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increased tumour Id as only the tumour specific light
chain was increased over control cultures. E-depleted TPA
stimulated culture supernatants from these patients
contained monotypic, tumour specific IgM (table 5-5). The
IgM levels in TPA stimulated E-depleted cultures were
significantly increased compared to TPA stimulated PBMNC
cultures in patient JR and MGr but decreased in patient
LG.
PBMNC cultures from the remaining patient (JSm,) were
negative for IgM (the tumour isotype,) but did contain
polyclonal IgG and IgA, which were increased after TPA
stimulation. After E-depletion only lambda light chains
were detected and were significantly increased after TPA
stimulation (p <0.02).
5.4.3 Group 3: Polyclonal Ig with a Single Isotype
The 4 patients in this group were all stage B or C. There
were 2 IgM and 2 IgG expressing tumours. Supernatants
from PBMNC cultures contained a single isotype,
corresponding to the tumour, but both kappa and lambda
light chains. All cultures showed increased Ig secretion
after TPA stimulation (table 5-6).
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E-depleted cells from 3 patients (RPa, WT, and MS,)
secreted monotypic tumour specific Ig after TPA
stimulation (table 5-7). In WT and MS the levels were
significantly reduced compared to PBMNC cultures while in
RPa they were unchanged.
No isotypes were detected in the control or TPA
stimulated E-depleted culture supernatants from LA but
tumour specific light chain was present and was increased
after TPA stimulation.
5.4.4 Group 4; Monot.vpic Ig
PBMNC culture supernatants from 3 patients with IgM
expressing tumours contained monotypic tumour Id after
TPA stimulation (table 5-8). Control cultures from
patient PM contained large amounts of tumour Id which was
greatly enhanced by TPA stimulation.
There was no significant difference in Ig levels between
TPA stimulated PBMNC and E-depleted cultures in patients
LC and GS whereas IgM levels in the E-depleted culture
from patient PM were significantly reduced compared to
the PBMNC culture (table 5.9).
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5.5 DISCUSSION
A previous study of TPA induced Ig secretion by PBMNC
cultures from CLL patients demonstrated increased tumour
specific Ig secretion in 18 out of 22 cases using an
ELISA assay similar to the one used here (Gordon et al,
1984b). All the tumours expressed IgM and no cultures
contained other isotypes or polyclonal Ig. Two other
studies reported a similar frequency of Ig secretion by
CLL cultures stimulated by phorbol esters but did not
attempt to demonstrate isotype or light chain restriction
in the secreted Ig (Cossman et al, 1982, and Polliack et
al, 1986). Deegan and Meada (1984,) reported increased
tumour specific Ig secretion in only 2 out of 9 CLLs but
used a haemolytic plaque assay which may be less
sensitive than the ELISA.
5.5*1 Polyclonal Ig Secretion by CLL PBMNC Cultures
The results in chapter 4 confirmed that the majority of
PBMNC cultures from CLL patients secrete Ig in response
to TPA stimulation. However, the finding of polyclonal Ig
in most of the supernatants was unexpected. This problem
had not been encountered in pilot studies but, for
convenience, these had used cells from patients who
attended the clinic regularly and who had high total
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white cell counts and relatively low numbers of T-cells.
As can be seen from the data presented this increases the
probability of monotypic Ig secretion.
TPA induced Ig secretion by normal B-cells in vitro is
enhanced by T-helper cells and monocytes (Sugawara,
1982,) and inhibited by T-suppressor cells (Ralph &
Kishimoto, 1982). It is known that T-helper/suppressor
ratios are abnormal in CLL, that absolute numbers of
T-suppressor cells are increased in advanced disease
(Kay et al, 1982,) and that T-helper/suppressor ratios
in CLL correlate positively with IgG and IgA serum
levels in vivo (Platsoucas et al, 1982). If the presence
of polyclonal Ig in CLL culture supernatants is dependent
on autologous T-cells then cultures from patients with
early stage disease who have relatively high numbers of
T-cells and high helper/suppressor ratios will be more
likely to produce polyclonal Ig. Conversely, PBMNC from
patients with advanced disease and high leukaemic cell
counts will contain fewer normal B-cells and fewer
T-cells with a lower helper/suppressor ratio and will
therefore be less likely to produce polyclonal Ig in
culture.
The estimation of T-cell numbers in cytospin preparations
stained by immunoperoxidase may not be as accurate as
suspension counts but did confirm the efficiency of
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T-cell depletion with only 1 E-depleted sample containing
more than 5% CD3 positive cells.
The results show that autologous T-cells can have a
marked effect on Ig secretion by residual normal B-cells
in PBMNC cultures from CLL patients. Cultures containing
the highest numbers of T-cells (table 5-1.) were most
likely to contain polyclonal Ig. However, the Ig levels
in control cultures show that the secretion of polyclonal
Ig is not due to TPA stimulation in these cases. Thus the
absence of polyclonal Ig in the previous report (Gordon
et al, 1984b,) must have been due to variation in culture
conditions or in the selection of patients for study.
The culture medium used here differed from that used by
Gordon et al (1984b,) in the addition of L-glutamine,
sodium pyruvate and HEPES buffer. A major difference,
however, could be batch variation in FCS which is used as
a supply of trace elements and growth factors. The FCS
used in our study had been selected for its efficiency at
supporting cell growth and may have been responsible for
inducing T-cell dependent Ig secretion by the small
numbers of non-malignant B-cells in the cultures.
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5.5.2 Light Chain Secretion b.v CLL Cultures
Supernatants in which no Ig isotype was detected but
which were positive for light chain were assumed to
contain free light chains. Intact Ig below the
sensitivity of the isotype assays (16ng/ml,) would give
similar results but was unlikely as the ODs for the light
chains were similar to other samples containing whole Ig
at levels above 16ng/ml.
In vitro production of free light chains was observed in
7 cases in which no isotype was detected and in three
patients light chain production was increased after TPA
stimulation. This contrasted with the experience of
Gordon et al (198k,) who found the secretion of free
light chains to be unaffected by TPA stimulation.
However, this could be due to the lower dose of TPA
(lOng/ml,) used in their study.
5.5.3 Tumour Idiotype Secretion b.v CLL Cultures
Eleven out of 15 E-depleted CLL cultures secreted tumour
Id in response to TPA stimulation. Of the remaining
cultures, 2 showed an increase in the tumour specific
light chain after TPA stimulation while the other two did
not secrete tumour specific Ig.
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Interestingly, IgM and IgG expressing tumours had
different patterns of Ig secretion. Cultures from 8 out
of 10 IgM expressing CLLs secreted tumour Id in response
to TPA and in 5 of these spontaneous tumour Id secretion
was detected in the control cultures. In contrast none of
the control cultures from IgG expressing tumours
contained tumour Id and only 2 cases secreted Id after
TPA stimulation.
This is consistent with the results of Gordon et al
(1984b,) who found that CLLs with an early B-cell
phenotype (cytoplasmic IgM in the absence of detectable
light chain, or surface IgM and IgD,) were more likely to
secrete tumour Id in response to TPA than cases with a
more mature B-cell phenotype (diffuse cytoplasmic IgM).
E-depletion had no consistent effect on the level of
tumour Id in comparison to PBMNC cultures. In IX cases Id
levels were reduced In E-depleted cultures, in 2 cases
they were increased, and in 3 cases they were not
significantly different.
The results show that whole
secretion by CLL cultures in
heterogeneous and can also
autologous T-cells.
Ig and free light chain
response to phorbol ester is
be independently affected by
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TABLE 5-1
T-Cell Subsets in Pre -Culture Samples before
and after E-Depletion
Pt. PBMNC E-Depleted Cells
CD3 CD/l CD8 CD3 CD£l CD8
AR 9 5 6 2 1 1
JSk 15 3 7 1 <1 1
JS 10 8 5 1 <1 <1
WC 16 10 3 U ND ND
JR 20 6 15 2 <1 2
JSm 8 5 2 <1 ND ND
MGr 19 11 10 3 1 <1
LG 29 13 Ik 6 3 5
RPa 1 <1 3 <1 <1 <1
WT <1 <1 <1 <1 <1 <1
MS 3 2 <1 <1 ND ND
LA 1 2 1 <1 ND ND
LC 8 U 3 <1 <1 <1
GS 1 <1 <1 <1 ND ND
PM 1 <1 1 <1 ND ND
All numbers are percentages of cells on cytospins
reacting with McAb against CD3, CD/I, or CD8 T-cell
antigens by immunoperoxidase.




Ig Levels in PBMNC Cultures from
Group 1 Samples
Patient IgG IgM IgA Kappa Lambda
(Isotype) ng/ml ng/ml ng/ml OD OD
AR Con 26 <16 <16 0. 53 0. 66
(IgMK) TPA 22 <16 <16 0. 53 0. 60
JSk Con 36 <16 <16 0. 1x8 0. 76
(IgGn) TPA 37 <16 <16 0. 62 0. 65
JS Con 1350 60 210 1. 21 1. 28
(IgGA) TPA 1500 72 230 1. 28 1. 23
WC Con 620 50 135 1. 03 1. 36
(IgGK) TPA U90 IX 5 100 1. 0IX 1. 36
TABLE 5.3
Ig Levels in E-Depleted Cultures from
Group 1 Samples
Patient IgG IgM IgA Kappa Lambda
(Isotype) ng/ml ng/ml ng/ml OD OD
AR Con <16 <16 <16 0. 12 0. 02
(IgMK) TPA <16 <16 <16 0. 15 0. 02
JSk Con <16 <16 <16 0. 1X2 0. 07
(IgGK) TPA 21 17 <16 0. 62 0. 07
JS Con 36 <16 <16 0. 55 o. ixix
(IgGA) TPA 1x6 <16 <16 0. 67 0. 1X3
WC Con <16 <16 <16 0. 17 0. 19
(IgGK) TPA <16 <16 <16 0. 27 0. 23
All results are means of duplicate wells. Isotypes
quantitated from standard curves Light chains expressed
in units of optical density
Con = control culture TPA = TPA stimulated culture
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TABLE 5-4
Ig Levels in PBMNC Cultures from
Group 2 Samples
Patient IgG IgM IgA Kappa Lambda
(Isotype) ng/ml ng/ml ng/ml OD OD
JR Con 125 28 100 1. 08 1. 48
(IgMA) TPA 88 110 72 1. 00 1. 69
JSm Con 13 <16 ao 0. 54 1. 36
(IgMA) TPA 100 <16 90 0. 96 1. 80
MGr Con 58 <16 <16 0. 86 1. 00
(IgMK) TPA 37 50 <16 0. 97 0. 89
LG Con 17 <16 <16 0. 42 0. 77
(IgMA) TPA 18 84 <16 0. 43 1. 41
rABLE 5.5
I g Levels in E-Depleted Cultures from
Group 2 Samples
Patient IgG IgM IgA Kappa Lambda
(Isotype) ng/ml ng/ml ng/ml OD OD
JR Con <16 16 <16 0. 12 0. 36
(IgMA) TPA <16 180 <16 0. 13 1. 00
JSm Con <16 <16 <16 0. 02 0. 28
(IgMA) TPA <16 <16 <16 0. 06 0. 58
MGr Con <16 <16 <16 0. 17 0. 07
(IgMK) TPA <16 8a <16 0. 48 0. 08
LG Con <16 <16 <16 0. 05 0. 15
(IgMA) TPA <16 32 <16 0. 05 0. 44
All results are means of duplicate wells. Isotypes
quantitated from standard curves Light chains expressed
in units of optical density
Con = control culture TPA = TPA stimulated culture
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TABLE 5-6
Ig Levels in PBMNC Cultures from
Group 3 Samples
Patient IgG IgM IgA Kappa Lambda
(Isotype) ng/ml ng/ml ng/ml OD OD
RP Con <16 16 <16 0. 29 0. 53
(IgMK) TPA <16 275 <16 0. 81 0. 45
WT Con <16 19 <16 0. 22 0. 37
(IgMK) TPA <16 240 <16 0. 88 0. 27
MS Con 21 16 <16 0. 61 0. 34
(IgGK) TPA 100 <16 <16 1. 97 0. 27
LA Con 26 <16 <16 0. 38 0. 42
( IgGK ) TPA 45 <16 <16 1. 10 0. 57
TABLE 5-7
Ig Levels in E-Depleted Cultures from
Group 3 Samples
Patient IgG IgM IgA Kappa Lambda
(Isotype) ng/ml ng/ml ng/ml OD OD
RP Con <16 16 <16 0. 07 0. 15
(IgMK) TPA <16 250 <16 0. 58 0. 17
WT Con <16 23 <16 0. 13 0. 01
(IgMK) TPA <16 110 <16 0. 53 0. 03
MS Con <16 <16 <16 0. 30 0. 01
(IgGK) TPA 46 <16 <16 1. 64 0. 06
LA Con <16 <16 <16 0. 34 0. 11
(IgGK) TPA <16 <16 <16 0. 72 0. 14
All results are means of duplicate wells. Isotypes
quantitated from standard curves Light chains expressed
in units of optical density
Con = control culture TPA = TPA stimulated culture
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TABLE 5.8
Ig Levels in PBMNC Cultures from
Group 4 Samples
Patient IgG IgM IgA v Kappa Lambda
ng/ml ng/ml ng/ml OD OD
LC Con <16 <16 <16 0. 21 0. 29
(IgMA) TPA <16 56 <16 0. 07 0. 50
GS Con <16 23 <16 0. Oil 0. 28
(IgMA) TPA <16 1300 <16 0. 08 >2
PM Con <16 700 <16 1. 30 0. 11
(IgMK) TPA <16 8000 <16 >2 0. 10
TABLE 5.9
Ig Levels in E-Depleted Cultures from
Group 4 Samples
Patient IgG IgM IgA Kappa Lambda
(Isotype) ng/ml ng/ml ng/ml OD OD
LC Con <16 <16 <16 0. 08 0. 23
(IgMA) TPA <16 41 <16 0. 05 0. 38
GS Con <16 84 <16 0. 02 0. 57
(IgMA) TPA <16 1100 <16 0. 02 >2
PM Con <16 720 <16 1. 17 0. 04
(IgMK) TPA <16 2900 <16 >2 0. 03
All results are means of
quantitated from standard
expressed in units of optical
Con = control culture
TPA = TPA stimulated culture
duplicate wells. Isotypes





This study has shown that it is possible to identify
shared idiotopes in CLL using a panel of V region
reactive monoclonal antibodies produced against a
randomly selected paraprotein.
Immunocytochemical studies had to be interpreted with
care because of cross-reactions between the JS McAbs and
epitopes expressed by molecules other than Ig. Such
cross-reactions are not surprising in view of idiotypic
diversity but they do emphasise the importance of
extensive characterisation of such antibodies.
Weak cross-reactions may not be of practical significance
in vivo as strong cross-linking of surface receptor is
generally required for the recruitment of cytotoxic
effectors (Hamblin et al, 1987).
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6.1 Expression of Shared Idlotopes in CLL
The division, by ELISA, of the V region associated
epitopes defined by the JS McAb panel into 3 groups
recognisable in normal Ig could be exploited to select
potentially useful antibodies for immunotherapy of B-cell
tumours.
Antibodies against private idiotopes, conventionally used
for anti-Id therapy (Thielemans et al, 1984, ) were shown
not to react significantly with either serum Ig or CLL
tumour Ids.
Antibodies against the public epitopes reacted with
14-29% of CLLs but are not attractive as therapeutic
agents because of the blocking potential of normal serum.
The expression of the public idiotopes by polyclonal Ig
in supernatants from CLL cultures containing less than 1%
normal B-cells confirmed that they were common to many
different clones.
Antibodies against restricted public epitopes have far
greater potential as therapeutic agents because the
blocking effects of normal serum are much lower. For
instance, the binding of normal IgG at 10|j.g/ml to
antibodies 47.7B3. 44.2A1, and 2H3.D6 is less than the
binding of JS paraprotein at lOng/ml in the ELISA assay
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(chapter 3). With a serum Ig concentration up to 20mg/ml
the potential serum blocking activity would be no greater
than 20ug/ml, well below the 30M.g/ml suggested as a
cut-off for choosing cross-reacting anti-Ids for therapy
(Stevenson et al, 1986).
In spite of similar binding to normal serum Ig the 3
antibodies recognising restricted public idiotopes differ
in their reactivities with the CLLs. The lambda specific
antibody Z17.7B3 reacts with 1 (5%) out of 21 lambda
expressing tumours and the heavy chain specific
antibodies HH.2A1 and 2H3.D6 react with 3 (7%) and 6
out of H2 cases respectively.
The level of expression of these restricted public
idiotopes in CLL is sufficient to make clinical trials
and, ultimately, routine therapy with pre-formed
antibodies a practical proposition.
6.2 Preferential Expression of Idiotope defined by
Antibody 2H3.D6 in CLL
In the original characterisation of the JS McAbs, 47.7B3
reacted with 2/72 (3%) lambda positive paraproteins while
ZU.2A1 and 2H3-D6 each reacted with 3/159 (2%)
paraproteins (Walker et al, 1987). The difference between
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McAb reactivity with the paraprotein panel and the CLL
group was compared using the chi-squared test with the
Yate's correction factor. The only antibody to show a
significant difference was 2H3.D6 which reacted more
frequently with the CLLs (p <0.01).
This preferential expression of an idiotope in CLL
compared to the B-cell tumours represented by the
paraprotein panel (mostly multiple myeloma and
Waldenstrom's Macroglobulinaemia,) could be due to a
number of reasons:-
Firstly, the high incidence of IgM positive CLLs (31/^2
cases,) could affect idiotype expression as somatic
mutation in B-cells appears to be associated with class
switching (Allen et al, 1987,) and, consequently, IgM
shows less idiotypic variation than other isotypes
(Bothwell et al, 1981 and, Gearhart et al, 1981).
However, the paraprotein panel used in the
characterisation of the JS McAbs included 36 IgM
paraproteins only one of which reacted with either /J.&.2A1
or 2H3.D6.
Secondly, CLL could be derived from a specific set of
B-cells with a limited idiotypic repertoire. Infrequent
cells in normal human lymph nodes and tonsils have a
phenotype similar to B-CLL cells (Caligaris-Cappio et al,
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1982). However, little is known about the relationship of
such cells to normal B-cell development or to CLL.
Thirdly, the preferentially expressed idiotope could be
the product of a specific V region gene rearrangement
associated with CLL.
A new family of Vh genes (Vh(V)), located close to the
Dh-Jh complex, have recently been described and were
rearranged in 9 out of 33 cases of CLL and 6 out of 16
cases of acute lymphoblastic leukaemia but not in 38 IgM
expressing Epstein-Barr Virus transformed human B-cell
lines (Shen et al, 1987, and Humphries et al, 1988).
Evidence from murine studies suggests that the Vh genes
nearest to the Dh-Jh complex are preferentially
rearranged in pre-B cells (Rathbun et al, 1987). If the
idiotope recognised by antibody 2H3.D6 is a product of
this gene family, its expression in CLL may be due to the
preferential use of the Vh(V) genes by B-cells frozen at
a specific stage of differentiation. The expression of
the idiotope in other classes of B-cell tumours as well
as genetic studies of those tumours reacting with 2H3-D6
would help clarify this.
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Finally, the preferential expression of this idiotope
could be due to an immunoregulatory defect commonly
associated with CLL. For instance, an abnormality of
idiotypic network regulation or an abnormal regulatory
T-cell clone may have driven B-cell clones expressing a
specific regulatory idiotope to autonomous proliferation.
Tumours such as myeloma, which do not express slg, would
not arise from such a mechanism and would therefore be
less likely to express the idiotope.
The reason(s) for the preferential expression of the
idiotope defined by 2H3.L6 in CLL compared to myeloma and
Waldenstrom's Macroglobulinaemia must remain a matter for
speculation at present.
In vitro studies comparing the effects of 2H3.D6 with
other JS McAbs on CLL cells expressing the relevant
idiotopes could demonstrate whether the preferentially
expressed idiotope has a particular role in cellular
regulation in this disease and would therefore be an
ideal target for anti-Id therapy.
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6.3 Factors Influencing the Outcome of Anti-Id Therapy
of Human B-Ceil Tumours
Experience has shown that it is possible to produce
polyclonal and monoclonal anti-Ids which are highly
specific for individual neoplastic B-lymphocyte clones
and which are capable of mediating tumour cell
destruction in vivo and in vitro. In spite of this the
results of anti-Id therapy of human B-cell malignancies
have been disappointing. The failure to produce a
sustained, beneficial response in all but one of the
patient's treated so far has been attributed to a number
of mechanisms (table 6.1) which are discussed below:
TABLE 6.1
Factors Influencing the Outcome of Anti-Id Therapy
Dose of anti-Id
Extracellular idiotype
Inaccessability of malignant cells
Reduced surface Ig density
Lack of effector cells
Host anti-mouse Ig immune response
Antigenic Modulation
Idiotype variant tumour cell populations
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6.3.1 Dose of Anti-Id
The purity and unlimited supply of monoclonal antibodies
allow the administration of large quantities of
therapeutic anti-Id with a minimum of side effects. In
the Stanford series patients received total doses of 400
- 3,183mg of anti-Id over 7 - 57 days (Meeker et al,
1985). Although there was no relationship between anti-Id
dose and a beneficial therapeutic response, no
anti-tumour effects were seen unless free serum anti-Id
could be detected.
Similar regimes have been used by others with up to lOg
of monoclonal anti-Id given to one patient over 17 days
(Capel et al, 1985, and Rankin et al, 1985).
Patients treated with polyclonal anti-Id have not
received such prolonged courses but have received up to
2g of purified anti-Id in single intravenous infusions
(Gordon et al, 1984a).
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6.3.2 Extracellular Idiotype
Serum Ig reacting with infused anti-Id could prevent the
therapeutic antibody from binding to the tumour cells.
In addition, Id/anti-Id immune complexes might have toxic
side effects and the clearance of such complexes could
significantly reduce the number of phagocytic cells
available for tumour cell destruction.
Binding to normal serum Ig is not a problem with anti-Ids
against private tumour determinants such as have been
used in therapeutic trials so far. However, many B-cell
tumours which are not commonly associated with serum
paraprotein bands by conventional electrophoresis have
been shown to secrete significant amounts of tumour Id by
more sensitive techniques such as ELISA assays (Meeker et
al, 1985, ) radio-immunoassays (Stevenson et al, 1980, )
and iso-electric focussing (Sinclair et al, 198/J-).
In the Stanford series the serum Id levels prior to
therapy ranged from 0 to 400p.g/ml. Significant side
effects were only seen in patients with serum Id levels
> lug/ml.
The blocking effect of low levels of serum Id can
probably be overcome by increasing the dose of anti-Id in
the majority of patients. Higher serum Id levels can be
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reduced by plasmapheresis prior to immunotherapy (Meeker
et al, 1985,) or by reduction of tumour mass with
conventional chemotherapy (Brown et al, 1980).
6.3.3 Inaccessabillty of Malignant Cells
Assuming successful anti-Id therapy requires antibody
binding to all tumour cells the infused antibody must
be able to penetrate all tissues containing malignant
cells.
In the Stanford series 6 out of 8 patients who had
biopsies of lymph nodes or marrow within 2U hours of
anti-Id therapy showed murine Ig bound to tumour cells
indicating successful penetration by anti-Id. One patient
with a malignant pleural effusion also had detectable
anti-Id levels in the pleural fluid within 2H hours
(Meeker et al, 1985).
Rankin et al (1985,) demonstrated that a lOmg infusion of
monoclonal anti-Id was sufficient to coat circulating
lymphoma cells in 2 patients with NHL but an intravenous
bolus of 150 - 300mg followed by a low dose infusion was
required to saturate tumour cells in lymph nodes and
marrow.
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6.3.4 Surface Ig Density
CLL cells are unusual in having a much lower surface Ig
density than normal lymphocytes (Ternynck et al, 1974, )
and most other Ig expressing B-cell tumours (Mason et al,
1980). As a consequence CLL cells may be more resistant
to complement mediated cytotoxicity for which the
number of cell membrane receptor molecules is critical
(Gordon et al, 1982). However, slg density is not
important for effective ADCC in vitro (Halloran and
Stylianos, 1980,) so the consequences for anti-Id therapy
of the reduced slg in CLL may depend on the mechanism of
action in vivo.
6.3.5 Lack of Effector Cells
Where anti-Id therapy is dependent on mechanisms such as
complement or ADCC the number of tumour cells may exceed
the capacity for cell lysis. Protection from tumour
challenge in a number of animal models of immunotherapy
was only seen when the tumour burden was low (reviewed by
Ritz and Schlossman, 1982). As a consequence it has been
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suggested that anti-Id therapy of humans should be
preceded by conventional cytotoxic therapy to reduce the
tumour mass. However, effective anti-Id therapy is
possible even when disease is advanced and widespread
(Miller et al, 1982).
6.3.6 Host Anti-Mouse Ig Response
In the Stanford series the repeated administration of
murine anti-Id was associated with the production of host
anti-mouse antibodies in 5 out of 11 patients (Meeker et
al, 1985). These cases had an increased incidence of
side effects and no further therapeutic benefit after
developing the anti-mouse Ig response which was therefore
considered a reason for terminating anti-Id therapy.
6.3*7 Antigenic Modulation
Originally described as cellular resistance to the
cytotoxic action of complement plus specific antibody due
to prior exposure to antibody (Boyse and Old, 1969,) this
phenomenon is due to redistribution, often followed by
endocytosis, of the surface receptor after binding by
antibody (Gordon and Stevenson, 1981). The process is
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rapid and reversible with affected cells re-expressing
the surface receptor 24 hours after removal of the
antibody.
Modulation was shown to be the mechanism of tumour escape
in treating acute lymphoblastic leukaemia with antibodies
against a differentiation antigen expressed by the
malignant cells (Ritz et al, 1981). It has also been
shown to occur in vivo after anti-Id therapy with
polyclonal (Gordon et al, 1984a,) and monoclonal (Capel
et al, 1985.) antibodies.
Since cross-linking of surface Ig by bivalent antibodies
is necessary for modulation (Gordon & Stevenson, 1981, )
the possibility of using univalent anti-Ids as
therapeutic antibodies has been explored by Stevenson's
group. Modulation of Li C guinea pig leukaemia cell slg in
vitro did not occur after exposure to univalent
derivatives of polyclonal anti-Id which still
effectively mediated both complement and ADCC lysis
(Glennie and Stevenson, 1982, and Stevenson et al, 1982).
Stevenson et al (1985, ) described the preparation of a
hybrid molecule in which an Fab' from polyclonal anti-Id
was coupled via thioether bonds to normal IgG. This has
the advantages of anti-idiotypic specificity and
univalency, combined with a human Fc receptor which is
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likely to be the most efficient at complement lysis or
ADCC in therapy.
A similar molecule derived from monoclonal anti-Id and
human IgG has been used to treat a human patient with CLL
(Hamblin et al, 1987). There was no evidence of
modulation and after il infusions the patient had achieved
a partial remission.
6.3.8 Idiotvpe Variant Tumour Cell Populations
Using panels of monoclonal anti-Ids each produced against
a specific tumour Carroll et al (1986,) examined biopsies
from 2 patients with follicular lymphomas by indirect
immunoperoxidase. They showed that the number of tumour
cells reacting with individual anti-Ids varied both at
different biopsy sites and over time.
The Stanford group have further investigated this
phenonemon using hybridoma technology to produce a
series of monoclonal tumour specific Ids each derived
from a single tumour cell from individual patients. The
amino acid sequence of individual tumour Id V regions can
be determined and related to differences in idiotope
expression (reviewed in Levy et al, 1987).
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Their results show that spontaneous somatic mutation of
Ig V region genes in B-cell tumours results in altered
idiotype expression so that phenotypically homogeneous
tumours may include a number of idiotypically distinct
sub-clones. Immunoglobulin gene rearrangement studies in
these and other cases (Raffeld et al, 1985,) confirmed
that the idiotype variant cell populations were derived
from the same original clone.
Biopsy from one patient whose tumour had become
resistant to anti-Id therapy contained tumour cells
which expressed surface Ig but were negative with the
therapeutic anti-Id. The altered idiotype was found to
be due to a single point mutation in the heavy chain
second hypervariable region (Cleary et al, 1986).
Altogether li patients in the Stanford series who had
temporary partial responses to anti-Id therapy had a
surface Ig positive. Id negative phenotype after
treatment (Miller et al, 1987),
Similar studies in the one patient who achieved a
complete remission demonstrated that somatic mutation
occurred in the V» genes as frequently as in the other
tumours but the anti-Id used in therapy still reacted
with all 6 tumour cell lines established suggesting that
the idiotope recognised was conserved by selective forces
- 171 -
within the host (Kon et al, 1987).
Thus anti-Id therapy with an antibody which does not
characterise the entire malignant clone may simply result
in a selective advantage for sub-clones which do not
express the idiotope concerned.
6.U Future Progress
Clinical trials have provided useful information about
the pharmacokinetics and potential toxicity of infused
anti-Id and have highlighted some of the reasons for
failure of therapy as well as the possible benefits.
The existence of idiotype variant tumour cell populations
both spontaneously and after therapy with anti-Id has
emerged as an important mechanism by which tumours can
escape the effects of monoclonal antibody therapy.
In addition, there are at least 2 fundamental problems
which, in the opinion of this author, are crucial to
improving the results of anti-Id therapy;
Firstly, the need to produce individual anti-Ids for
each patient to be treated has limited the number of
patients involved in trials and could also limit the
practical application of this therapy.
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Secondly, lack of understanding both about the biology of
B-cell tumours and the mechanisms of effective anti-Id
therapy means there is no logical basis for selecting the
patients to be treated or the most appropriate
therapeutic antibodies.
Evidence from animal models suggests that the induction
of idiotype-specific regulatory T-cells is the likeliest
mechanism by which idiotypic manipulation could result in
the long term control of a malignant B-cell clone. It is
not clear whether this also applies in humans nor whether
the administration of antibodies reacting with tumour Id
is the most effective method of inducing such a response.
In vitro studies using cells from human B-cell tumours
or B-cell lines could be used to investigate the effects
of anti-Ids on cellular proliferation and metabolism. For
instance, it may be possible to define tumour associated
idiotopes which are susceptible to T-cell regulation.
However, a fundamental limitation of such studies is that
they cannot mimic or predict the effects of anti-Id
administered in vivo.
Human clinical trials have to be the ultimate test of
the efficacy of anti-Id therapy. However, the treatment
of small numbers of patients with randomly generated
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anti-Ids against private determinants is unlikely to
provide sufficient information to be able to identify
either the patients most likely to respond to therapy or
the most appropriate anti-Ids to use.
This study has demonstrated that it is possible to define
idiotopes which are not strongly expressed in normal
serum Ig but which recur at reasonable frequencies in
CLL. In addition, there is evidence that idiotopes can be
preferentially expressed by different classes of B-cell
tumours. These results have important implications for
anti-Id therapy:
i. Antibodies against shared idiotopes which are also
regulatory idiotopes (Bona et al, 1987,) may be
more effective than conventional therapeutic
anti-Ids at inducing a host immunoregulatory
response capable of long term control of the
malignant B-cell clone.
ii. Idiotopes which are conserved by the immune system
may be less prone to somatic mutation than private
idiotopes and would, therfore, be more likely to
characterise the entire malignant clone.
iii. Pre-formed antibodies against shared idiotopes
expressed by B-cell tumours would make this
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therapy more practical. Larger numbers of patients
could be treated with standardised antibodies
allowing a more effective analysis of the factors
which determine the outcome of therapy.
The extension of this work to include other classes of
B-cell tumours and the generation of other V region
reactive antibody panels will allow larger clinical
trials to be established. In addition, antibodies against
idiotopes which are preferentially expressed by single
classes of B-cell tumour may prove to be the ideal
therapeutic agents and may be powerful tools for
investigating the biology of these diseases in vitro.
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